US20240043423A1 - Compounds and methods for treatment of hedgehog pathway associated conditions - Google Patents
Compounds and methods for treatment of hedgehog pathway associated conditions Download PDFInfo
- Publication number
- US20240043423A1 US20240043423A1 US18/366,553 US202318366553A US2024043423A1 US 20240043423 A1 US20240043423 A1 US 20240043423A1 US 202318366553 A US202318366553 A US 202318366553A US 2024043423 A1 US2024043423 A1 US 2024043423A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- hydrogen
- mmol
- aryl
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000037361 pathway Effects 0.000 title claims abstract description 14
- 241000289669 Erinaceus europaeus Species 0.000 title claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract description 212
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000012453 solvate Substances 0.000 claims abstract description 22
- 239000000651 prodrug Substances 0.000 claims abstract description 20
- 229940002612 prodrug Drugs 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims description 104
- 239000001257 hydrogen Substances 0.000 claims description 104
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 94
- 239000000243 solution Substances 0.000 claims description 62
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical group 0.000 claims description 50
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 43
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 40
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 25
- 229910003827 NRaRb Inorganic materials 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
- -1 cachets Substances 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 16
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 208000000172 Medulloblastoma Diseases 0.000 claims description 12
- 229910052701 rubidium Inorganic materials 0.000 claims description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 5
- 206010000830 Acute leukaemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 5
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 206010028537 myelofibrosis Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 235000010603 pastilles Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 9
- 230000008410 smoothened signaling pathway Effects 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 3
- 208000037765 diseases and disorders Diseases 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 124
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- 238000005160 1H NMR spectroscopy Methods 0.000 description 78
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 78
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- 239000004698 Polyethylene Substances 0.000 description 67
- 239000011541 reaction mixture Substances 0.000 description 67
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 53
- 239000007832 Na2SO4 Substances 0.000 description 51
- 229910052938 sodium sulfate Inorganic materials 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 50
- 239000000741 silica gel Substances 0.000 description 50
- 229910002027 silica gel Inorganic materials 0.000 description 50
- 229960001866 silicon dioxide Drugs 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 49
- 239000007787 solid Substances 0.000 description 47
- 238000004440 column chromatography Methods 0.000 description 46
- 239000000284 extract Substances 0.000 description 43
- 239000000706 filtrate Substances 0.000 description 40
- 239000003921 oil Substances 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 26
- 239000012267 brine Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 238000001816 cooling Methods 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 8
- RCTDOCMVBQZGPO-UHFFFAOYSA-N ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(=O)C2CCC2)CC(C(=O)OCC)(C)C)C=C1 Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(=O)C2CCC2)CC(C(=O)OCC)(C)C)C=C1 RCTDOCMVBQZGPO-UHFFFAOYSA-N 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 239000007821 HATU Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- XNAPQGPHGKDZCS-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-3-(2,2-dimethylpropylsulfanyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)SCC(C)(C)C)CC(C(=O)OCC)(C)C)C=C1 XNAPQGPHGKDZCS-UHFFFAOYSA-N 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- HEBPPWFUXDUUAA-UHFFFAOYSA-N 1-N-[(2-chlorophenyl)methyl]-4-methoxybenzene-1,2-diamine Chemical compound NC1=CC(OC)=CC=C1NCC1=CC=CC=C1Cl HEBPPWFUXDUUAA-UHFFFAOYSA-N 0.000 description 5
- UJTUFDCBTJPDFU-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-methoxyindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)OC)C(CC(C)(C)C)=O)CC(C(=O)O)(C)C)C=C1 UJTUFDCBTJPDFU-UHFFFAOYSA-N 0.000 description 5
- LTPCODUDRHUVGH-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(cyclobutanecarbonyl)-5-propan-2-ylpyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C=3C2=NC=C(C=3)C(C)C)C(=O)C2CCC2)CC(C(=O)O)(C)C)C=C1 LTPCODUDRHUVGH-UHFFFAOYSA-N 0.000 description 5
- IRHQCFWVMDKBEB-UHFFFAOYSA-N 3-[3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(C(=O)C2=C(N(C3=CC(=CC=C23)C(C)C)CC2CCC2)CC(C(=O)O)(C)C)C=C1 IRHQCFWVMDKBEB-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 244000060234 Gmelina philippensis Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- LVXCDNNMZJAPOG-UHFFFAOYSA-N ethyl 5-bromo-2,2-dimethyl-4-oxopentanoate Chemical compound CCOC(=O)C(C)(C)CC(=O)CBr LVXCDNNMZJAPOG-UHFFFAOYSA-N 0.000 description 5
- JOLZUPPVNMMVAK-UHFFFAOYSA-N ethyl 5-tert-butylsulfanyl-2,2-dimethyl-4-oxopentanoate Chemical compound CCOC(=O)C(C)(C)CC(=O)CSC(C)(C)C JOLZUPPVNMMVAK-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- MMUGBKNNMQBWRV-UHFFFAOYSA-N methyl 3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-methoxyindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)OC)C(CC(C)(C)C)=O)CC(C(=O)OC)(C)C)C=C1 MMUGBKNNMQBWRV-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- GNHVXUYQTRDICK-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-1-(4-propan-2-ylphenyl)hydrazine Chemical compound C1=CC(C(C)C)=CC=C1N(N)CC1=CC=C(Cl)C=C1 GNHVXUYQTRDICK-UHFFFAOYSA-N 0.000 description 4
- VJXOPWJIOOVNGN-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutyl)-2-(3-hydroxy-2,2-dimethylpropyl)indol-5-ol Chemical compound C1(Cl)=CC=C(CN2C(=C(C3=CC(=CC=C23)O)CCC(C)(C)C)CC(C)(C)CO)C=C1 VJXOPWJIOOVNGN-UHFFFAOYSA-N 0.000 description 4
- MKGCTWIBVCPXHU-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-hydroxyindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)O)C(CC(C)(C)C)=O)CC(C(=O)O)(C)C)C=C1 MKGCTWIBVCPXHU-UHFFFAOYSA-N 0.000 description 4
- UTOADYYMOUTUMU-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxyindol-2-yl]-2,2-dimethylpropanamide Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)OC)CC1=CC=C(C=C1)Cl)CC(C(=O)N)(C)C UTOADYYMOUTUMU-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- USFFJYMEQLEDDE-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-3-(2,2-dimethylpropylsulfinyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)S(=O)CC(C)(C)C)CC(C(=O)OCC)(C)C)C=C1 USFFJYMEQLEDDE-UHFFFAOYSA-N 0.000 description 4
- XDDFKUCCEMCQGV-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=CC3=CC(=CC=C23)C(C)C)CC(C(=O)OCC)(C)C)C=C1 XDDFKUCCEMCQGV-UHFFFAOYSA-N 0.000 description 4
- HZTCCISWRZQSRU-UHFFFAOYSA-N ethyl 5-bromo-4-oxopentanoate Chemical compound CCOC(=O)CCC(=O)CBr HZTCCISWRZQSRU-UHFFFAOYSA-N 0.000 description 4
- WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- DUVUVUMDCUSUBA-UHFFFAOYSA-N methyl 3-[3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(C(=O)C2=C(N(C3=CC(=CC=C23)C(C)C)CC2CCC2)CC(C(=O)OC)(C)C)C=C1 DUVUVUMDCUSUBA-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- BYJCRUCIXAVEBY-UHFFFAOYSA-N (3-propan-2-ylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC(C)C1=CC=CC(N[NH3+])=C1 BYJCRUCIXAVEBY-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- RPDOFXGYFUBZLN-UHFFFAOYSA-N 1-(4,4-dibromobut-3-en-2-yl)-4-(2-methylpropyl)benzene Chemical compound BrC(=CC(C1=CC=C(CC(C)C)C=C1)C)Br RPDOFXGYFUBZLN-UHFFFAOYSA-N 0.000 description 3
- OMEXNYMHASCSKW-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-1-(4-methoxyphenyl)hydrazine Chemical compound C1=CC=C(CN(C2=CC=C(C=C2)OC)N)C(Cl)=C1 OMEXNYMHASCSKW-UHFFFAOYSA-N 0.000 description 3
- GRODTGGKTHWULW-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-2-[1-[4-(2-methylpropyl)phenyl]ethyl]benzimidazole-5-carbonitrile Chemical compound CC(C)Cc1ccc(cc1)C(C)c1nc2cc(ccc2n1Cc1ccccc1Cl)C#N GRODTGGKTHWULW-UHFFFAOYSA-N 0.000 description 3
- HNNNGIIPZDXCNA-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-2-[4-(2-methylpropyl)phenyl]benzimidazol-5-ol Chemical compound C1=CC=C(C(=C1)CN1C2=C(N=C1C1=CC=C(CC(C)C)C=C1)C=C(C=C2)O)Cl HNNNGIIPZDXCNA-UHFFFAOYSA-N 0.000 description 3
- UBGPOUIJQWJZOW-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-5-methoxy-2-[4-(2-methylpropyl)phenyl]benzimidazole Chemical compound C1=CC(=C(C=C1)CN1C2=C(N=C1C1=CC=C(CC(C)C)C=C1)C=C(C=C2)OC)Cl UBGPOUIJQWJZOW-UHFFFAOYSA-N 0.000 description 3
- HKPFRGPGFZCIDC-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-2-[1-[4-(2-methylpropyl)phenyl]ethyl]indol-5-ol Chemical compound C1=CC=C(C=C1CN1C(=CC2=CC(=CC=C12)O)C(C1=CC=C(CC(C)C)C=C1)C)Cl HKPFRGPGFZCIDC-UHFFFAOYSA-N 0.000 description 3
- GZZLPDCOTQRCLH-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-methoxy-2-[1-[4-(2-methylpropyl)phenyl]ethyl]indole Chemical compound C1=CC(=CC(=C1)CN1C(C(C2=CC=C(CC(C)C)C=C2)C)=CC2=CC(=CC=C12)OC)Cl GZZLPDCOTQRCLH-UHFFFAOYSA-N 0.000 description 3
- DQVSPHVDHURYLJ-UHFFFAOYSA-N 1-[4-(2-methylpropyl)phenyl]propan-2-one Chemical compound CC(C)CC1=CC=C(CC(C)=O)C=C1 DQVSPHVDHURYLJ-UHFFFAOYSA-N 0.000 description 3
- BHNFDOWGCDXOOK-UHFFFAOYSA-N 1-bromo-4,4-dimethylpentan-2-one Chemical compound CC(C)(C)CC(=O)CBr BHNFDOWGCDXOOK-UHFFFAOYSA-N 0.000 description 3
- IKGNKWPXLRDBBP-UHFFFAOYSA-N 1-but-3-yn-2-yl-4-(2-methylpropyl)benzene Chemical compound CC(C)CC1=CC=C(C(C)C#C)C=C1 IKGNKWPXLRDBBP-UHFFFAOYSA-N 0.000 description 3
- BASMANVIUSSIIM-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1Cl BASMANVIUSSIIM-UHFFFAOYSA-N 0.000 description 3
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 3
- SVLSIKWUURLBGI-UHFFFAOYSA-N 1-tert-butylsulfanyl-4,4-dimethylpentan-2-one Chemical compound CC(C)(C)CC(=O)CSC(C)(C)C SVLSIKWUURLBGI-UHFFFAOYSA-N 0.000 description 3
- PFDBEACWLCHWRZ-UHFFFAOYSA-N 2-(4-bromophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(Br)C=C1 PFDBEACWLCHWRZ-UHFFFAOYSA-N 0.000 description 3
- HKHNEYIHCJUAPM-UHFFFAOYSA-N 2-[1-(4-bromophenyl)ethyl]-1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazole Chemical compound BrC1=CC=C(C=C1)C(C)C1=NC2=C(N1CC1=C(C=CC=C1)Cl)C=CC(=C2)OC HKHNEYIHCJUAPM-UHFFFAOYSA-N 0.000 description 3
- JHPXYXKUHXMILR-UHFFFAOYSA-N 2-[1-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxyindol-2-yl]-2-methylpropan-2-yl]-4-methyl-1,3-oxazole Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)OC)CC1=CC=C(C=C1)Cl)CC(C)(C)C=1OC=C(N=1)C JHPXYXKUHXMILR-UHFFFAOYSA-N 0.000 description 3
- DMZVZANOMJGHKO-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]propanal Chemical compound CC(C)CC1=CC=C(C(C)C=O)C=C1 DMZVZANOMJGHKO-UHFFFAOYSA-N 0.000 description 3
- HAQLWFYGSSJSNT-UHFFFAOYSA-N 2-[4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]phenyl]acetic acid Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C=C2)CC(=O)O)C=CC=C1 HAQLWFYGSSJSNT-UHFFFAOYSA-N 0.000 description 3
- OGZPWVSXQQFRIQ-UHFFFAOYSA-N 2-[4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]phenyl]acetonitrile Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C=C2)CC#N)C=CC=C1 OGZPWVSXQQFRIQ-UHFFFAOYSA-N 0.000 description 3
- NFFZZHMNLDKKQE-UHFFFAOYSA-N 2-[4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]phenyl]ethanol Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C=C2)CCO)C=CC=C1 NFFZZHMNLDKKQE-UHFFFAOYSA-N 0.000 description 3
- YBAGMTVKDRIMTB-UHFFFAOYSA-N 2-bromo-4-methoxyaniline Chemical compound COC1=CC=C(N)C(Br)=C1 YBAGMTVKDRIMTB-UHFFFAOYSA-N 0.000 description 3
- YZPGGRJYHOLIQN-UHFFFAOYSA-N 2-bromo-N-[(3-chlorophenyl)methyl]-4-methoxyaniline Chemical compound BrC1=C(NCC2=CC(=CC=C2)Cl)C=CC(=C1)OC YZPGGRJYHOLIQN-UHFFFAOYSA-N 0.000 description 3
- NVUZBFCZHOUCGI-UHFFFAOYSA-N 3-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)CC(C(=O)O)(C)C)C=CC=C1 NVUZBFCZHOUCGI-UHFFFAOYSA-N 0.000 description 3
- YXPKKQOEWZJUNF-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(cyclobutanecarbonyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(=O)C2CCC2)CC(C(=O)O)(C)C)C=C1 YXPKKQOEWZJUNF-UHFFFAOYSA-N 0.000 description 3
- KPEVFIYNENORJA-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-(cyclobutylmethyl)-6-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound C(C)(C)(C)SC1=C(N(C2=CC(=CC=C12)C(C)C)CC1CCC1)CC(C(=O)O)(C)C KPEVFIYNENORJA-UHFFFAOYSA-N 0.000 description 3
- ZHUSOIPZNWSHSC-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxyindol-2-yl]-2,2-dimethylpropanenitrile Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)OC)CC1=CC=C(C=C1)Cl)CC(C#N)(C)C ZHUSOIPZNWSHSC-UHFFFAOYSA-N 0.000 description 3
- OLDKOJKNNDXDSQ-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxyindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound OC(=O)C(C)(C)CC1=C(SC(C)(C)C)C2=CC(OC)=CC=C2N1CC1=CC=C(Cl)C=C1 OLDKOJKNNDXDSQ-UHFFFAOYSA-N 0.000 description 3
- YNZQDBJSWJFBNM-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxypyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoic acid Chemical compound C(C)(C)(C)SC1=C(N(C2=NC=C(C=C21)OC)CC1=CC=C(C=C1)Cl)CC(C(=O)O)(C)C YNZQDBJSWJFBNM-UHFFFAOYSA-N 0.000 description 3
- KQOQBLKXTMMFQW-UHFFFAOYSA-N 3-bromo-5-methoxypyridin-2-amine Chemical compound COC1=CN=C(N)C(Br)=C1 KQOQBLKXTMMFQW-UHFFFAOYSA-N 0.000 description 3
- YEDINTUDFIZHIC-UHFFFAOYSA-N 3-bromo-5-propan-2-ylpyridin-2-amine Chemical compound C1(=CC(=CN=C1N)C(C)C)Br YEDINTUDFIZHIC-UHFFFAOYSA-N 0.000 description 3
- QUVVOEQEYSKMSX-UHFFFAOYSA-N 3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-2-(2,2-dimethylpropyl)-5-propan-2-ylindole Chemical compound C1=CC(=CC=C1CN1C(=C(C2=CC(C(C)C)=CC=C12)SC(C)(C)C)CC(C)(C)C)Cl QUVVOEQEYSKMSX-UHFFFAOYSA-N 0.000 description 3
- VOVAWUIVORUAKN-UHFFFAOYSA-N 3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-2-[2-methyl-2-(4-methyl-1,3-oxazol-2-yl)propyl]indol-5-ol Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)O)CC1=CC=C(C=C1)Cl)CC(C)(C=1OC=C(N=1)C)C VOVAWUIVORUAKN-UHFFFAOYSA-N 0.000 description 3
- ZRJXKRFVYRFVED-UHFFFAOYSA-N 3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxy-2-[2-methyl-2-(2H-tetrazol-5-yl)propyl]indole Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)OC)CC1=CC=C(C=C1)Cl)CC(C)(C1=NN=NN1)C ZRJXKRFVYRFVED-UHFFFAOYSA-N 0.000 description 3
- MUWWNHTXQLFLKN-UHFFFAOYSA-N 4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]benzoic acid Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C(=O)O)C=C2)C=CC=C1 MUWWNHTXQLFLKN-UHFFFAOYSA-N 0.000 description 3
- JKTWBUSCQXOEFL-UHFFFAOYSA-N 4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]benzonitrile Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C#N)C=C2)C=CC=C1 JKTWBUSCQXOEFL-UHFFFAOYSA-N 0.000 description 3
- XYLDQSOICRRSDF-UHFFFAOYSA-N 4-bromo-1-N-[(2-chlorophenyl)methyl]benzene-1,2-diamine Chemical compound NC1=CC(Br)=CC=C1NCC1=CC=CC=C1Cl XYLDQSOICRRSDF-UHFFFAOYSA-N 0.000 description 3
- BEZIHKCIWUBLJU-UHFFFAOYSA-N 4-bromo-n-[(2-chlorophenyl)methyl]-2-nitroaniline Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1NCC1=CC=CC=C1Cl BEZIHKCIWUBLJU-UHFFFAOYSA-N 0.000 description 3
- NENLLFGJFVVZEU-UHFFFAOYSA-N 4-methoxy-3,3-dimethyl-4-oxobutanoic acid Chemical compound COC(=O)C(C)(C)CC(O)=O NENLLFGJFVVZEU-UHFFFAOYSA-N 0.000 description 3
- NWAAYOPSGFNXAS-UHFFFAOYSA-N 5-[1-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxyindol-2-yl]-2-methylpropan-2-yl]-3-ethyl-1,2,4-oxadiazole Chemical compound C1=C(C=CC(=C1)CN1C(=C(C2=CC(OC)=CC=C12)SC(C)(C)C)CC(C)(C)C1=NC(=NO1)CC)Cl NWAAYOPSGFNXAS-UHFFFAOYSA-N 0.000 description 3
- VROUVXMCGZZZGS-UHFFFAOYSA-N 5-bromo-1-[(2-chlorophenyl)methyl]-2-[1-[4-(2-methylpropyl)phenyl]ethyl]benzimidazole Chemical compound BrC1=CC2=C(N(C(=N2)C(C)C2=CC=C(C=C2)CC(C)C)CC2=C(C=CC=C2)Cl)C=C1 VROUVXMCGZZZGS-UHFFFAOYSA-N 0.000 description 3
- GXSWKKZGLOYAPE-UHFFFAOYSA-N 5-propan-2-ylpyridin-2-amine Chemical compound CC(C)C1=CC=C(N)N=C1 GXSWKKZGLOYAPE-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NZULPUFIMSWGHC-UHFFFAOYSA-N C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)O)CC1=CC=C(C=C1)Cl)CC(C)(C1=NN=NN1C)C Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)O)CC1=CC=C(C=C1)Cl)CC(C)(C1=NN=NN1C)C NZULPUFIMSWGHC-UHFFFAOYSA-N 0.000 description 3
- MRGWBRMLKXZGKM-UHFFFAOYSA-N C1=CC(=C(C=C1)CN1C2=C(C=C(C=C2)C(=O)O)N=C1C(C1=CC=C(C=C1)CC(C)C)C)Cl Chemical compound C1=CC(=C(C=C1)CN1C2=C(C=C(C=C2)C(=O)O)N=C1C(C1=CC=C(C=C1)CC(C)C)C)Cl MRGWBRMLKXZGKM-UHFFFAOYSA-N 0.000 description 3
- OIXOWAQCWMZUHR-UHFFFAOYSA-N CON(C)C(=O)Cc1ccc(CC(C)C)cc1 Chemical compound CON(C)C(=O)Cc1ccc(CC(C)C)cc1 OIXOWAQCWMZUHR-UHFFFAOYSA-N 0.000 description 3
- BWYAPTKLRUSSSZ-UHFFFAOYSA-N ClC1=CC=C(CN2C(=C(C=3C2=NC=C(C=3)OC)I)CC(C(=O)OCC)(C)C)C=C1 Chemical compound ClC1=CC=C(CN2C(=C(C=3C2=NC=C(C=3)OC)I)CC(C(=O)OCC)(C)C)C=C1 BWYAPTKLRUSSSZ-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- HBOKRFXXJLOJPR-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-4-methoxy-2-[3-[4-(2-methylpropyl)phenyl]but-1-ynyl]aniline Chemical compound ClC=1C=C(CNC2=C(C=C(C=C2)OC)C#CC(C)C2=CC=C(C=C2)CC(C)C)C=CC=1 HBOKRFXXJLOJPR-UHFFFAOYSA-N 0.000 description 3
- JCCXVJOBPYDMSJ-UHFFFAOYSA-N N-[2-[(2-chlorophenyl)methylamino]-5-methoxyphenyl]-4-(2-methylpropyl)benzamide Chemical compound ClC1=C(CNC2=C(C=C(C=C2)OC)NC(C2=CC=C(C=C2)CC(C)C)=O)C=CC=C1 JCCXVJOBPYDMSJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000000984 Sauvagesia erecta Species 0.000 description 3
- GENBXZQMZXIMRT-UHFFFAOYSA-N [4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]phenyl]methanol Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C=C2)CO)C=CC=C1 GENBXZQMZXIMRT-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XDPQVTCYKCEWAT-UHFFFAOYSA-N dimethyl 2,2-dimethylbutanedioate Chemical compound COC(=O)CC(C)(C)C(=O)OC XDPQVTCYKCEWAT-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- HUIWJKFZJWFCIU-UHFFFAOYSA-N ethyl 2,2-dimethyl-3-(5-propan-2-yl-1H-pyrrolo[2,3-b]pyridin-2-yl)propanoate Chemical compound C(C)(C)C=1C=C2C(=NC=1)NC(=C2)CC(C(=O)OCC)(C)C HUIWJKFZJWFCIU-UHFFFAOYSA-N 0.000 description 3
- BNAGEFAQCJICKW-UHFFFAOYSA-N ethyl 3-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate Chemical compound COC=1C=C2C(=NC=1)NC(=C2)CC(C(=O)OCC)(C)C BNAGEFAQCJICKW-UHFFFAOYSA-N 0.000 description 3
- PLZNAYFXFDGNOK-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-5-phenylmethoxyindol-2-yl]-2,2-dimethylpropanoate Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=C(N(C2=CC=1)CC1=CC=C(C=C1)Cl)CC(C(=O)OCC)(C)C PLZNAYFXFDGNOK-UHFFFAOYSA-N 0.000 description 3
- LDVZISUHELVPGU-UHFFFAOYSA-N ethyl 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxypyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoate Chemical compound C(C)(C)(C)SC1=C(N(C2=NC=C(C=C21)OC)CC1=CC=C(C=C1)Cl)CC(C(=O)OCC)(C)C LDVZISUHELVPGU-UHFFFAOYSA-N 0.000 description 3
- FIKYWADOQVYCRU-UHFFFAOYSA-N ethyl 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CC1=C(SC(C)(C)C)C2=CC(C(C)C)=CC=C2N1CC1=CC=C(Cl)C=C1 FIKYWADOQVYCRU-UHFFFAOYSA-N 0.000 description 3
- BJCJYXTVNBGEOQ-UHFFFAOYSA-N ethyl 4-bromopent-4-enoate Chemical compound CCOC(=O)CCC(Br)=C BJCJYXTVNBGEOQ-UHFFFAOYSA-N 0.000 description 3
- QVPAHMHJYDYAOS-UHFFFAOYSA-N ethyl 4-chloro-2,2-dimethylpent-4-enoate Chemical compound CCOC(=O)C(C)(C)CC(Cl)=C QVPAHMHJYDYAOS-UHFFFAOYSA-N 0.000 description 3
- BBDJJOMIPMWTTC-UHFFFAOYSA-N ethyl 5-(2-amino-5-methoxypyridin-3-yl)-2,2-dimethylpent-4-ynoate Chemical compound NC1=NC=C(C=C1C#CCC(C(=O)OCC)(C)C)OC BBDJJOMIPMWTTC-UHFFFAOYSA-N 0.000 description 3
- VWHMBLNSCCYZDA-UHFFFAOYSA-N ethyl 5-(2-amino-5-propan-2-ylpyridin-3-yl)-2,2-dimethylpent-4-ynoate Chemical compound NC1=NC=C(C=C1C#CCC(C(=O)OCC)(C)C)C(C)C VWHMBLNSCCYZDA-UHFFFAOYSA-N 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- KZWKRXZFJWFHSR-UHFFFAOYSA-N methyl 2-(4-bromophenyl)propanoate Chemical compound COC(=O)C(C)C1=CC=C(Br)C=C1 KZWKRXZFJWFHSR-UHFFFAOYSA-N 0.000 description 3
- JAUPBSZCTAUUGQ-UHFFFAOYSA-N methyl 3-[1-(cyclobutylmethyl)-6-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound C1(CCC1)CN1C(=CC2=CC=C(C=C12)C(C)C)CC(C(=O)OC)(C)C JAUPBSZCTAUUGQ-UHFFFAOYSA-N 0.000 description 3
- HNXYHRJRYPPCHW-UHFFFAOYSA-N methyl 3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-hydroxyindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)O)C(CC(C)(C)C)=O)CC(C(=O)OC)(C)C)C=C1 HNXYHRJRYPPCHW-UHFFFAOYSA-N 0.000 description 3
- HNGKITRRFJSGLG-UHFFFAOYSA-N methyl 3-[3-tert-butylsulfanyl-1-(cyclobutylmethyl)-6-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound C(C)(C)(C)SC1=C(N(C2=CC(=CC=C12)C(C)C)CC1CCC1)CC(C(=O)OC)(C)C HNGKITRRFJSGLG-UHFFFAOYSA-N 0.000 description 3
- JRQLHRJGQKUCEQ-UHFFFAOYSA-N methyl 4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]benzoate Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C(=O)OC)C=C2)C=CC=C1 JRQLHRJGQKUCEQ-UHFFFAOYSA-N 0.000 description 3
- COKMPXHFPNPLHV-UHFFFAOYSA-N methyl 4-[2-[(2-chlorophenyl)methylamino]-5-methoxyanilino]-2,2-dimethyl-4-oxobutanoate Chemical compound ClC1=C(CNC2=C(C=C(C=C2)OC)NC(CC(C(=O)OC)(C)C)=O)C=CC=C1 COKMPXHFPNPLHV-UHFFFAOYSA-N 0.000 description 3
- AKRCGRWIDZTQKK-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-4-methoxy-2-nitroaniline Chemical compound [O-][N+](=O)C1=CC(OC)=CC=C1NCC1=CC=CC=C1Cl AKRCGRWIDZTQKK-UHFFFAOYSA-N 0.000 description 3
- FQOSZELLQXJGPI-UHFFFAOYSA-N n-methoxy-n-methyl-2-[4-(2-methylpropyl)phenyl]propanamide Chemical compound CON(C)C(=O)C(C)C1=CC=C(CC(C)C)C=C1 FQOSZELLQXJGPI-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- FHOIDTSUTPSKTK-UHFFFAOYSA-N tert-butyl n-(5-prop-1-en-2-ylpyridin-2-yl)carbamate Chemical compound CC(=C)C1=CC=C(NC(=O)OC(C)(C)C)N=C1 FHOIDTSUTPSKTK-UHFFFAOYSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- TUVXODQWCIJUAY-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-2-methyl-3-[4-(2-methylpropyl)phenyl]indol-5-ol Chemical compound C1=CC=C(C(=C1)CN1C(=C(C2=CC(=CC=C12)O)C1=CC=C(CC(C)C)C=C1)C)Cl TUVXODQWCIJUAY-UHFFFAOYSA-N 0.000 description 2
- JPEJCNWUFQHFCB-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-5-methoxy-2-[1-[4-(2-methylpropyl)phenyl]ethyl]benzimidazole Chemical compound C=1C=C(CC(C)C)C=CC=1C(C)C1=NC2=CC(OC)=CC=C2N1CC1=CC=CC=C1Cl JPEJCNWUFQHFCB-UHFFFAOYSA-N 0.000 description 2
- DFIWWCRVTOKNBF-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-5-methoxy-2-methyl-3-[4-(2-methylpropyl)phenyl]indole Chemical compound C1=CC=CC(=C1CN1C(=C(C2=C1C=CC(OC)=C2)C1=CC=C(CC(C)C)C=C1)C)Cl DFIWWCRVTOKNBF-UHFFFAOYSA-N 0.000 description 2
- BCDPVUFIAUOHRL-UHFFFAOYSA-N 1-[1-[(4-chlorophenyl)methyl]-2-(3-hydroxy-2,2-dimethylpropyl)-5-methoxyindol-3-yl]-3,3-dimethylbutan-1-one Chemical compound C1=CC(=CC=C1CN1C(=C(C2=CC(OC)=CC=C12)C(=O)CC(C)(C)C)CC(C)(C)CO)Cl BCDPVUFIAUOHRL-UHFFFAOYSA-N 0.000 description 2
- IQLACDFDAIRLCJ-UHFFFAOYSA-N 1-[1-[(4-chlorophenyl)methyl]-5-hydroxy-2-(3-hydroxy-2,2-dimethylpropyl)indol-3-yl]-3,3-dimethylbutan-1-one Chemical compound C1=C(C=CC(=C1)CN1C(=C(C2=C1C=CC(O)=C2)C(=O)CC(C)(C)C)CC(C)(C)CO)Cl IQLACDFDAIRLCJ-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- BATJQHPCBCAIHB-UHFFFAOYSA-N 2-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]acetic acid Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)C(C)C)CC1=CC=C(C=C1)Cl)CC(=O)O BATJQHPCBCAIHB-UHFFFAOYSA-N 0.000 description 2
- IYAYESKREWZMTQ-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(2,2-dimethylpropylsulfanyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)SCC(C)(C)C)CC(C(=O)O)(C)C)C=C1 IYAYESKREWZMTQ-UHFFFAOYSA-N 0.000 description 2
- UXGFZJAMIUUXLQ-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(2,2-dimethylpropylsulfinyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)S(=O)CC(C)(C)C)CC(C(=O)O)(C)C)C=C1 UXGFZJAMIUUXLQ-UHFFFAOYSA-N 0.000 description 2
- DTZIHFQPVKGOSH-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(2,2-dimethylpropylsulfonyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)S(=O)(=O)CC(C)(C)C)CC(C(=O)O)(C)C)C=C1 DTZIHFQPVKGOSH-UHFFFAOYSA-N 0.000 description 2
- NTFLZCUBUFPARQ-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-3-(2-methylpropanoyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(C(C)C)=O)CC(C(=O)O)(C)C)C=C1 NTFLZCUBUFPARQ-UHFFFAOYSA-N 0.000 description 2
- KWOZLKWPBYKUSY-UHFFFAOYSA-N 3-[3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-hydroxyindol-2-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=CC=C(C(=O)C2=C(N(C3=CC(=CC=C23)O)CC2CCC2)CC(C(=O)O)(C)C)C=C1 KWOZLKWPBYKUSY-UHFFFAOYSA-N 0.000 description 2
- GXWWIQYWLSFDNL-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]propanoic acid Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)C(C)C)CC1=CC=C(C=C1)Cl)CCC(=O)O GXWWIQYWLSFDNL-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- CXGKRZPZMABGQU-UHFFFAOYSA-N 3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-2-[2-methyl-2-(2-methyltetrazol-5-yl)propyl]indol-5-ol Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)O)CC1=CC=C(C=C1)Cl)CC(C)(C=1N=NN(N=1)C)C CXGKRZPZMABGQU-UHFFFAOYSA-N 0.000 description 2
- IWGBSKDYNFHJKT-UHFFFAOYSA-N 3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxy-2-[2-methyl-2-(1-methyltetrazol-5-yl)propyl]indole Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)OC)CC1=CC=C(C=C1)Cl)CC(C)(C1=NN=NN1C)C IWGBSKDYNFHJKT-UHFFFAOYSA-N 0.000 description 2
- FRFZDWQGAHRKND-UHFFFAOYSA-N 3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxy-2-[2-methyl-2-(2-methyltetrazol-5-yl)propyl]indole Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)OC)CC1=CC=C(C=C1)Cl)CC(C)(C=1N=NN(N=1)C)C FRFZDWQGAHRKND-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VDQZVCVKBAYFER-UHFFFAOYSA-N C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)O)CC1=CC=C(C=C1)Cl)CC(C)(C)C1=NC(=NO1)CC Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)O)CC1=CC=C(C=C1)Cl)CC(C)(C)C1=NC(=NO1)CC VDQZVCVKBAYFER-UHFFFAOYSA-N 0.000 description 2
- NRKHRHHSOWZXOE-UHFFFAOYSA-N CCOC(C(C)(C)CC1=C(C(CC(C)(C)C)=O)C2=CC(C(C(C)(C)C)C(O)=O)=CC=C2N1CC(C=C1)=CC=C1Cl)=O Chemical compound CCOC(C(C)(C)CC1=C(C(CC(C)(C)C)=O)C2=CC(C(C(C)(C)C)C(O)=O)=CC=C2N1CC(C=C1)=CC=C1Cl)=O NRKHRHHSOWZXOE-UHFFFAOYSA-N 0.000 description 2
- HEROCANLBMLBCI-UHFFFAOYSA-N ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(C(C)C)=O)CC(C(=O)OCC)(C)C)C=C1 Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(C(C)C)=O)CC(C(=O)OCC)(C)C)C=C1 HEROCANLBMLBCI-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- JVIMTZKDPIEVNB-UHFFFAOYSA-N ethyl 2,2-dimethylpent-4-ynoate Chemical compound CCOC(=O)C(C)(C)CC#C JVIMTZKDPIEVNB-UHFFFAOYSA-N 0.000 description 2
- VFJGHAZXIWVYKX-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-3-(2,2-dimethylpropylsulfonyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)S(=O)(=O)CC(C)(C)C)CC(C(=O)OCC)(C)C)C=C1 VFJGHAZXIWVYKX-UHFFFAOYSA-N 0.000 description 2
- BRJGLRHACMYUHY-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-3-(cyclobutanecarbonyl)-5-propan-2-ylpyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C=3C2=NC=C(C=3)C(C)C)C(=O)C2CCC2)CC(C(=O)OCC)(C)C)C=C1 BRJGLRHACMYUHY-UHFFFAOYSA-N 0.000 description 2
- LXXZDKDIGYCDRQ-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-5-methoxypyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoate Chemical compound C(C)OC(C(CC1=CC=2C(=NC=C(C=2)OC)N1CC1=CC=C(C=C1)Cl)(C)C)=O LXXZDKDIGYCDRQ-UHFFFAOYSA-N 0.000 description 2
- CZQAAJSJLJXQML-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-5-propan-2-ylpyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoate Chemical compound C1=C(C=CC(=C1)CN1C(=CC2=C1N=CC(=C2)C(C)C)CC(C)(C(=O)OCC)C)Cl CZQAAJSJLJXQML-UHFFFAOYSA-N 0.000 description 2
- MSRMFZBBBXGISH-UHFFFAOYSA-N ethyl 5-(2,2-dimethylpropylsulfanyl)-2,2-dimethyl-4-oxopentanoate Chemical compound CC(C(=O)OCC)(CC(CSCC(C)(C)C)=O)C MSRMFZBBBXGISH-UHFFFAOYSA-N 0.000 description 2
- BUFRWXOJVQWVMP-UHFFFAOYSA-N ethyl 5-tert-butylsulfanyl-4-oxopentanoate Chemical compound CCOC(=O)CCC(=O)CSC(C)(C)C BUFRWXOJVQWVMP-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- GMXFZBZOVZOYNQ-UHFFFAOYSA-N hydron;(3-methoxyphenyl)hydrazine;chloride Chemical compound Cl.COC1=CC=CC(NN)=C1 GMXFZBZOVZOYNQ-UHFFFAOYSA-N 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LECRLHWEACLQDU-UHFFFAOYSA-N methyl 2-[4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]phenyl]acetate Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)C(C)C2=CC=C(C=C2)CC(=O)OC)C=CC=C1 LECRLHWEACLQDU-UHFFFAOYSA-N 0.000 description 2
- TVUJDLBJYVDLDB-UHFFFAOYSA-N methyl 4-tert-butylsulfanyl-3-oxobutanoate Chemical compound COC(=O)CC(=O)CSC(C)(C)C TVUJDLBJYVDLDB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 2
- 229960005325 sonidegib Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- GOKPFEIEGAIOLH-UHFFFAOYSA-N tert-butyl N-(5-propan-2-ylpyridin-2-yl)carbamate Chemical compound C(C)(C)C=1C=CC(=NC=1)NC(OC(C)(C)C)=O GOKPFEIEGAIOLH-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960004449 vismodegib Drugs 0.000 description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 1
- LMFPPUVGWDZXMB-UHFFFAOYSA-N (4-propan-2-ylphenyl)hydrazine;hydrochloride Chemical compound Cl.CC(C)C1=CC=C(NN)C=C1 LMFPPUVGWDZXMB-UHFFFAOYSA-N 0.000 description 1
- WASMBKQCOOGYLH-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-5-methoxy-3-[4-(2-methylpropyl)phenyl]indole Chemical compound C1=CC=C(C(=C1)CN1C=C(C2=CC(OC)=CC=C12)C1=CC=C(CC(C)C)C=C1)Cl WASMBKQCOOGYLH-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- FVMVSRHYHAREGQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-1-(4-propan-2-ylphenyl)hydrazine;hydrochloride Chemical compound Cl.C1=CC(C(C)C)=CC=C1N(N)CC1=CC=C(Cl)C=C1 FVMVSRHYHAREGQ-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- DDGRAFHHXYIQQR-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1 DDGRAFHHXYIQQR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LSUXMVNABVPWMF-UHFFFAOYSA-N 2,2-dimethylpropane-1-thiol Chemical compound CC(C)(C)CS LSUXMVNABVPWMF-UHFFFAOYSA-N 0.000 description 1
- YMFWYDYJHRGGPF-UHFFFAOYSA-N 2,3-dibromoprop-1-ene Chemical compound BrCC(Br)=C YMFWYDYJHRGGPF-UHFFFAOYSA-N 0.000 description 1
- FALCMQXTWHPRIH-UHFFFAOYSA-N 2,3-dichloroprop-1-ene Chemical compound ClCC(Cl)=C FALCMQXTWHPRIH-UHFFFAOYSA-N 0.000 description 1
- XNTGHAOFAMUJKV-UHFFFAOYSA-N 2-(4-bromophenyl)-N-[2-[(2-chlorophenyl)methylamino]-5-methoxyphenyl]propanamide Chemical compound BrC1=CC=C(C=C1)C(C(=O)NC1=C(C=CC(=C1)OC)NCC1=C(C=CC=C1)Cl)C XNTGHAOFAMUJKV-UHFFFAOYSA-N 0.000 description 1
- QXVRLFIKHYCFJS-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]propanoyl chloride Chemical compound CC(C)CC1=CC=C(C(C)C(Cl)=O)C=C1 QXVRLFIKHYCFJS-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- VZIVJMAPXLLGNQ-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-5-methoxypyrrolo[2,3-b]pyridin-2-yl]-2,2-dimethylpropanoic acid Chemical compound CC(C)(CC1=CC2=CC(=CN=C2N1CC3=CC=C(C=C3)Cl)OC)C(=O)O VZIVJMAPXLLGNQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XCCNRBCNYGWTQX-UHFFFAOYSA-N 3-propan-2-ylaniline Chemical compound CC(C)C1=CC=CC(N)=C1 XCCNRBCNYGWTQX-UHFFFAOYSA-N 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- AZASWMGVGQEVCS-UHFFFAOYSA-N 4,4-dimethylpentan-2-one Chemical compound CC(=O)CC(C)(C)C AZASWMGVGQEVCS-UHFFFAOYSA-N 0.000 description 1
- APGFKFVPGXOPPO-UHFFFAOYSA-N 4-(2-methylpropyl)benzoyl chloride Chemical compound CC(C)CC1=CC=C(C(Cl)=O)C=C1 APGFKFVPGXOPPO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- QFMJFXFXQAFGBO-UHFFFAOYSA-N 4-methoxy-2-nitroaniline Chemical compound COC1=CC=C(N)C([N+]([O-])=O)=C1 QFMJFXFXQAFGBO-UHFFFAOYSA-N 0.000 description 1
- PPVACAYMHWCCMK-UHFFFAOYSA-N 5-(2,2-dimethylpropylsulfanyl)-2,2-dimethyl-4-oxopentanoic acid Chemical compound CC(C)(C)CSCC(=O)CC(C)(C)C(=O)O PPVACAYMHWCCMK-UHFFFAOYSA-N 0.000 description 1
- XJKJHILCYUUVSJ-UHFFFAOYSA-N 5-methoxypyridin-2-amine Chemical compound COC1=CC=C(N)N=C1 XJKJHILCYUUVSJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SJJCSPNGZPZVDU-UHFFFAOYSA-N ClC1=CC=C(C(=O)C2=C(N(C3=CC(=CC=C23)O)CC2CCC2)CC(C(=O)OCC)(C)C)C=C1 Chemical compound ClC1=CC=C(C(=O)C2=C(N(C3=CC(=CC=C23)O)CC2CCC2)CC(C(=O)OCC)(C)C)C=C1 SJJCSPNGZPZVDU-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YTCLZZMGSVVBIE-UHFFFAOYSA-N N-[5-bromo-2-[(2-chlorophenyl)methylamino]phenyl]-2-[4-(2-methylpropyl)phenyl]propanamide Chemical compound BrC=1C=CC(=C(C=1)NC(C(C)C1=CC=C(C=C1)CC(C)C)=O)NCC1=C(C=CC=C1)Cl YTCLZZMGSVVBIE-UHFFFAOYSA-N 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- HXNNSNLGMUIKGK-UHFFFAOYSA-N [1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-2-(3-ethoxy-2,2-dimethyl-3-oxopropyl)indol-5-yl] 3,3-dimethylbutanoate Chemical compound C1=C(C=CC(CN2C(=C(C3=CC(=CC=C23)OC(=O)CC(C)(C)C)C(=O)CC(C)(C)C)CC(C)(C)C(=O)OCC)=C1)Cl HXNNSNLGMUIKGK-UHFFFAOYSA-N 0.000 description 1
- ZKXIQVPWPFMKPS-UHFFFAOYSA-N [4-[1-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]ethyl]phenyl]methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC=C(C=C1)C(C)C1=NC2=C(N1CC1=C(C=CC=C1)Cl)C=CC(=C2)OC ZKXIQVPWPFMKPS-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N azain Natural products C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VMINKOHQLDFUBP-UHFFFAOYSA-N ethyl 3-(3-tert-butylsulfanyl-6-propan-2-yl-1H-indol-2-yl)-2,2-dimethylpropanoate Chemical compound C(C)(C)(C)SC1=C(NC2=CC(=CC=C12)C(C)C)CC(C(=O)OCC)(C)C VMINKOHQLDFUBP-UHFFFAOYSA-N 0.000 description 1
- QXXPXAGTRIJTSD-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=C(C3=CC(=CC=C23)C(C)C)C(CC(C)(C)C)=O)CC(C(=O)OCC)(C)C)C=C1 QXXPXAGTRIJTSD-UHFFFAOYSA-N 0.000 description 1
- GHVZTSZTZABENB-UHFFFAOYSA-N ethyl 3-[1-[(4-chlorophenyl)methyl]-5-hydroxyindol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=CC=C(CN2C(=CC3=CC(=CC=C23)O)CC(C(=O)OCC)(C)C)C=C1 GHVZTSZTZABENB-UHFFFAOYSA-N 0.000 description 1
- JPXNJCVPJOZELR-UHFFFAOYSA-N ethyl 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-methoxyindol-2-yl]-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CC1=C(SC(C)(C)C)C2=CC(OC)=CC=C2N1CC1=CC=C(Cl)C=C1 JPXNJCVPJOZELR-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- QHJOWSXZDCTNQX-UHFFFAOYSA-N methyl 2-(4-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=C(Br)C=C1 QHJOWSXZDCTNQX-UHFFFAOYSA-N 0.000 description 1
- FXUHIJCOPBFVNO-UHFFFAOYSA-N methyl 2-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]acetate Chemical compound C(C)(C)(C)SC1=C(N(C2=CC=C(C=C12)C(C)C)CC1=CC=C(C=C1)Cl)CC(=O)OC FXUHIJCOPBFVNO-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- NWQFJUWSZMMDMO-UHFFFAOYSA-N methyl 3-[1-[(2-chlorophenyl)methyl]-5-methoxybenzimidazol-2-yl]-2,2-dimethylpropanoate Chemical compound ClC1=C(CN2C(=NC3=C2C=CC(=C3)OC)CC(C(=O)OC)(C)C)C=CC=C1 NWQFJUWSZMMDMO-UHFFFAOYSA-N 0.000 description 1
- HFLMYYLFSNEOOT-UHFFFAOYSA-N methyl 4-chloro-3-oxobutanoate Chemical compound COC(=O)CC(=O)CCl HFLMYYLFSNEOOT-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- RLZPCFQNZGINRP-UHFFFAOYSA-N n'-hydroxypropanimidamide Chemical compound CCC(N)=NO RLZPCFQNZGINRP-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- CKXAMCSVTNPSCZ-UHFFFAOYSA-N tert-butyl n-(5-bromopyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(Br)C=N1 CKXAMCSVTNPSCZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- This invention relates to compounds, pharmaceutical compositions, and methods for treatment of hedgehog pathway associated malignancies.
- Medulloblastoma is the most common malignant brain tumor in children. Despite current tumor therapies including surgery, chemotherapy and radiotherapy, a significant proportion of patients still succumb to this disease. Moreover, patients who survive medulloblastoma, often suffer from long-term side effects including cognitive deficits and endocrine disorders. Improved strategies to treat medulloblastoma are still urgently needed.
- Hh pathway activation is also found in many other human malignancies such as basal cell carcinoma and pancreatic cancers.
- two Hh pathway antagonists are FDA approved including vismodegib and sonidegib.
- This invention meets the foregoing need by providing novel compounds as Hh pathway antagonists, which inhibit Hh signaling and repress medulloblastma cell growth. Therefore, the present invention represents a new type of chemotherapeutic approach to treat hedgehog pathway-associated malignancies. Different from conventional chemotherapeutic drugs that directly kill tumor cells by cytotoxicity, these compounds repress tumor cell growth through induction of tumor cells differentiation.
- the present invention provides a compound of formula (I):
- the present invention provides Exemplified compounds in Table 1 and Examples in List 1 (below), and pharmaceutically acceptable salts, solvates, or prodrugs thereof.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to any embodiments disclosed here, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.
- the present invention provides a method of treating a disease or disorder associated with hedgehog pathway, the method comprising administering to a subject in need of treatment a therapeutically effective amount of a compound according to any one embodiment disclosed herein, or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutical composition thereof.
- the present invention provides use of the compounds disclosed herein, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treatment of a disease or disorder associated with hedgehog signaling pathway.
- the present invention in one aspect, provides novel heterocyclic compounds, including, including but not limited to indole and benzimidazole compounds, among others, and analogs, especially those characterized by formula (I), useful as therapeutic agents for treatment of diseases or disorders associated with hedgehog signaling pathway based on a new discovery that these compounds can inhibit hedgehog signaling pathway in a mammalian animal.
- novel heterocyclic compounds including, including but not limited to indole and benzimidazole compounds, among others, and analogs, especially those characterized by formula (I), useful as therapeutic agents for treatment of diseases or disorders associated with hedgehog signaling pathway based on a new discovery that these compounds can inhibit hedgehog signaling pathway in a mammalian animal.
- the present invention provides an indole compound of formula (II):
- the compounds of formula (II) are further defined as follows:
- the present invention provides a benzimidazole compound of formula (III):
- the present invention provides a pyrrolo[2,3-b]pyridine compound of formula (IV):
- the present invention provides a pyrrolo[3,2-b]pyridine compound of formula (V):
- the present invention provides a compound according to any one of Formulas (I), (II), (III), (IV), and (V), wherein (where applicable):
- R 9 is C 1 -C 8 alkyl or C 3 -C 6 cycloalkyl
- the present invention provides exemplified compounds in Table 1 and the following list (List 1), and pharmaceutically acceptable salts, solvates, or prodrugs thereof:
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to any embodiments disclosed here, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.
- the present invention provides a method of treating a disease or disorder associated with hedgehog pathway, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound according to any one embodiment disclosed herein, or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutical composition thereof.
- the present invention provides use of any of the compounds disclosed herein, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treatment of a disease or disorder associated with hedgehog signaling pathway.
- the diseases and disorders that can be treated using the compounds disclosed herein include, but are not limited to, malignancies associated with hedgehog signaling pathway, for example, medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer, and chondrosarcoma, etc.
- malignancies associated with hedgehog signaling pathway for example, medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer,
- the preferred subjects for treatment include mammalian animals, including humans, horses, dogs, cats, or the like, and more preferably humans.
- compositions or formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. Regardless of the route of administration selected, the active ingredient(s) are formulated into pharmaceutically acceptable dosage forms by methods known to those of skill in the art.
- the amount of the active ingredient(s) which will be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration and all of the other factors described above.
- the amount of the active ingredient(s) which will be combined with a carrier material to produce a single dosage form will generally be that amount of the active ingredient(s) which is the lowest dose effective to produce a therapeutic effect.
- Methods of preparing pharmaceutical formulations or compositions include the step of bringing the active ingredient(s) into association with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly mixing the active ingredient(s) into liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Exemplary, non-limiting examples of formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of the active ingredient(s).
- the prodrug(s), active ingredient(s) in their micronized form
- one or more pharmaceutically-acceptable carriers known to those of skill in the art.
- suitable aqueous and nonaqueous carriers include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- suitable mixtures thereof Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size, and by the use of surfactants.
- compositions may also contain adjuvants such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like in the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- the absorption of the drug in order to prolong the effect of the active ingredient(s), it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the active ingredient(s) then depends upon its/their rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a lyophilized condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
- sterile liquid carrier for example water for injection
- Extemporaneous injection solutions and suspensions maybe prepared from sterile powders, granules and tablets of the type described above.
- aryl, cycloalkyl, heteroaryl, and heterocyclyl groups of the present disclosure may be substituted as described in each of their respective definitions.
- aryl part of an arylalkyl group such as benzyl may be substituted as described in the definition of the term “aryl.”
- alkoxy refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.
- Representative examples of alkoxy group include, but are not limited to, methoxy (CH 3 O—), ethoxy (CH 3 CH 2 O—), or the like.
- alkyl refers to a group derived from a straight or branched chain saturated hydrocarbon by removal of a hydrogen from one of the saturated carbons.
- the alkyl group preferably contains from one to ten, sometimes preferably one to six, and sometimes more preferably one to four, carbon atoms.
- Representative examples of alkyl group include, but are not limited to, methyl, ethyl, isopropyl, and tert-butyl.
- aryl refers to a group derived from an aromatic carbocycle by removal of a hydrogen atom from an aromatic ring.
- the aryl group can be monocyclic, bicyclic or polycyclic.
- Representative examples of aryl groups include phenyl and naphthyl, sometimes more preferably phenyl.
- benzyl refers to a methyl group on which one of the hydrogen atoms is replaced by a phenyl group, wherein said phenyl group may be substituted by one or more substituents.
- Representative examples of benzyl group include, but are not limited to, PhCH 2 —, 4-MeO—C 6 H 4 CH 2 —, and 2,4,6-tri-methyl-C 6 H 4 CH 2 —.
- cyano refers to —CN.
- cycloalkyl refers to a group derived from a monocyclic saturated carbocycle, having preferably three to eight, and sometimes more preferably three to six carbon atoms, by removal of a hydrogen atom from the saturated carbocycle.
- Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl.
- halo and “halogen,” as used herein, refer to F, Cl, Br, or I.
- haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
- haloalkyl refers to an alkyl group substituted by at least one halogen atom.
- the haloalkyl group can be an alkyl group of which all hydrogen atoms are substituted by halogens.
- Representative examples of haloalkyl include, but are not limited to, trifluoromethyl (CF 3 —), 2,2,2-trifluoroethyl (CF 3 CH 2 —).
- heteroaryl refers to a group derived from a monocyclic or bicyclic compound comprising at least one aromatic ring comprising one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur, by removal of a hydrogen atom from the aromatic ring.
- aromatic rings have less aromatic character than their all-carbon counterparts.
- a heteroaryl group need only have some degree of aromatic character.
- heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, pyrimidinyl, furyl, thienyl, isoxazolyl, thiazolyl, isoxazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, benzothiazolyl, and benzothienyl.
- heterocyclyl refers to a group derived from a monocyclic or bicyclic compound comprising at least one nonaromatic ring comprising one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur, by removal of a hydrogen atom from the nonaromatic ring.
- the heterocyclyl groups of the present disclosure can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom in the group.
- heterocyclyl groups include, but are not limited to, morpholinyl, oxazolidinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, thiomorpholinyl, and indolinyl.
- hydroxy or “hydroxyl,” as used herein, refer to —OH.
- nitro refers to —NO 2 .
- any group for example, alkyl, alkenyl, “cycloalkyl,” “aryl,” “heterocyclyl,” or “heteroaryl”, is said to be “optionally substituted,” unless specifically defined, it means that the group is or is not substituted by from one to five, preferably one to three, substituents independently selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, hydroxy, oxo, C 1-6 acyl, cyano, nitro, and amino (optionally substituted by one or two C 1-6 alkyl groups), or the like, provided that such substitution would not violate the conventional bonding principles known to a person of ordinary skill in the art.
- the phrase “optionally substituted” is used before a list of groups, it means that each one of the groups listed may be optionally substituted.
- the compounds of the present disclosure can exist as pharmaceutically acceptable salts or solvates.
- pharmaceutically acceptable salt means any non-toxic salt that, upon administration to a recipient, is capable of providing the compounds or the prodrugs of a compound of this invention.
- the salts can be prepared during the final isolation and purification of the compounds or separately by reacting a suitable nitrogen atom with a suitable acid.
- Acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, hydrogen bisulfide as well as organic acids, such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid acid, and related inorganic and organic acids.
- organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid,
- Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
- a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
- the cations of pharmaceutically acceptable salts include, but are not limited to, lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, and N-methylmorpholine.
- nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, and N-methylmorpholine.
- solvate means a physical association of a compound of this invention with one or more, preferably one to three, solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more, preferably one to three, solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
- terapéuticaally effective amount refers to the total amount of each active component that is sufficient to show a meaningful patient benefit, e.g., a sustained reduction in viral load.
- a meaningful patient benefit e.g., a sustained reduction in viral load.
- the term refers to that ingredient alone.
- the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously.
- pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- patient includes both human and other mammals.
- treating refers to: (i) preventing a disease, disorder or condition from occurring in a patient that may be predisposed to the disease, disorder, and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder, or condition, i.e., arresting its development; and (iii) relieving the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and/or condition.
- the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
- the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
- the compound 10 was prepared by the method similar to the compound ethyl 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate (compound 2) in the step 1.7, but using isobutyryl chloride.
- the compound 9 was prepared by the method similar to the example 1, but using ethyl 3-(1-(4-chlorobenzyl)-3-isobutyryl-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate in the step 1.8.
- the compound 12 was prepared by the method similar to the compound ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate in the step 3.2, but using ethyl 5-(tert-butylthio)-4-oxopentanoate (C4).
- the compound 11 was prepared by the method similar to the compound ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate in the step 3.3, but using compound ethyl 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate.
- the compound 14 was prepared by the method similar with ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate (compound 4) in step 3.2, but using methyl 4-(tert-butylthio)-3-oxobutanoate(C4′).
- the compound 13 was prepared by the method similar to the compound 1 in the step 1.8, but using compound methyl 2-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)acetate (compound 14).
- the compound 29 was prepared by the method similar to the compound 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid, but using (3-methoxyphenyl)hydrazine hydrochloride (step 13.2).
- the compound 30 was prepared by the method similar to the compound methyl 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate, but using (3-methoxyphenyl)hydrazine hydrochloride (step 13.2).
- the compound H4 was prepared by the method similar to the compound B3 in example 1, but using different aniline as the starting material.
- the compound H5 was prepared by the similar method to the prepararat on of compound 1 in the step 1.8.
- the compound 56 was prepared by the method similar to example 22.
- tumor cells were isolated from medulloblastoma developed from mice with deficiency in Patched1 gene. Tumor cells were plated in vitro as previously described, and treated with various concentration of compounds for 48 hours. Tumor cells cultured were then harvested to measure cell survival based on MTT assay. The IC 50 value for each compound was calculated using Prism the statistical software.
- Table 1 summarizes the IC 50 data obtained using MB assay for exemplary compounds of the invention.
- IC 50 values are shown as A, B, C, or D.
- A represents IC 50 value between 1.0 ⁇ M and 5.0 ⁇ M; B is between 5.0 ⁇ M and 10 ⁇ M; C is between 10 ⁇ M to 20 ⁇ M; and D indicates greater than 20 ⁇ M.
- IC 50 results of exemplary compounds Compound Number Structure IC 50 1 A 2 D 3 A 4 D 5 D 6 C 7 C 8 C 9 C 10 D 11 B 12 D 13 C 14 D 15 D 16 C 17 D 18 D 19 D 20 A 21 D 22 D 23 B 24 A 25 D 26 A 27 B 28 D 29 D 30 D 31 D 32 A 33 D 34 B 35 B or 36 B or 37 C or 38 A or 39 B 40 D 41 D 42 D 43 D 44 D 45 D 46 C 47 D 48 D 49 A 50 C 51 B 52 D 53 C 54 D 55 A 56 D 57 D 58 D
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
This invention presents the novel compounds of formula (I), (II), (III), (IV), and (V) as described in the specification, and pharmaceutically acceptable salts, solvates, and prodrugs, and compositions thereof, and methods of measuring hedgehog pathway activation in tumor cells, examining tumor cell proliferation, differentiation and apoptosis and using the compounds and pharmaceutical compositions disclosed for treatment of diseases and disorders associated with the hedgehog signaling pathway.
Description
- This application is a divisional of patent application Ser. No. 17/255,413, filed on Dec. 22, 2020, which is the U.S. national phase application of International Application No. PCT/IB2019/055338, filed on Jun. 25, 2019, which claims priority to U.S. Provisional Patent Application No. 62/689,470, filed on Jun. 25, 2018, the disclosures of which are incorporated herein by reference in their entirety.
- This invention relates to compounds, pharmaceutical compositions, and methods for treatment of hedgehog pathway associated malignancies.
- Medulloblastoma is the most common malignant brain tumor in children. Despite current tumor therapies including surgery, chemotherapy and radiotherapy, a significant proportion of patients still succumb to this disease. Moreover, patients who survive medulloblastoma, often suffer from long-term side effects including cognitive deficits and endocrine disorders. Improved strategies to treat medulloblastoma are still urgently needed.
- Approximately 30% of human medulloblastoma is associated with aberrant activation of hedgehog (Hh) pathway. Hh pathway activation is also found in many other human malignancies such as basal cell carcinoma and pancreatic cancers. Currently two Hh pathway antagonists are FDA approved including vismodegib and sonidegib.
- Although these antagonists exhibited promising efficacies in inhibiting medulloblastoma growth in the initial stage of clinical trial, patients often developed resistant rapidly. Moreover, vismodegib and sonidegib unspecifically inhibited Hh pathway in tumor cells and normal cells, which caused severe adverse effects, in particular, permanently compromised bone development. Due to the above reasons, these two drugs are currently not approved to be used for medulloblastoma treatment.
- Therefore, there is a clear need to develop new therapeutic agents for treatment of such Hh pathway-associated diseases and disorders.
- This invention meets the foregoing need by providing novel compounds as Hh pathway antagonists, which inhibit Hh signaling and repress medulloblastma cell growth. Therefore, the present invention represents a new type of chemotherapeutic approach to treat hedgehog pathway-associated malignancies. Different from conventional chemotherapeutic drugs that directly kill tumor cells by cytotoxicity, these compounds repress tumor cell growth through induction of tumor cells differentiation.
- In one aspect, the present invention provides a compound of formula (I):
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
-
- G is N or CR5;
- A is N or CR6;
- B is N or CR7;
- R1 is C1-8 alkyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, C6-10 aryl, —(C1-6 alkylene)-C3-6 cycloalkyl, —(C1-6 alkylene)-C6-10 aryl, or —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl), each optionally substituted;
- R2 is hydrogen, C1-8 alkyl, C6-10 aryl, —C(O)OR8, —C(O)NRaRb, —(C1-6 alkylene)-C6-10 aryl, —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl), —(C1-6 alkylene)-C(O)OR8, or —(C1-6 alkylene)-C(O)NRaRb, each except hydrogen optionally substituted;
- R3 is hydrogen, halogen, hydroxyl, optionally substituted C1-6 alkyl, C1-4 alkoxy, optionally substituted C3-6 cycloalkyl, or —C(O)OR11;
- R4 is hydrogen, halogen, hydroxyl, or optionally substituted C1-6 alkyl;
- R5 is hydrogen, optionally substituted C1-8 alkyl, optionally substituted C6-10 aryl, optionally substituted 5- to 10-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)R10 (n is 0, 1, or 2);
- R6 is hydrogen, halogen, or optionally substituted C1-6 alkyl;
- R7 is hydrogen, halogen, or optionally substituted C1-6 alkyl;
- R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl, each exception hydrogen optionally substituted;
- R9 is hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
- R10 is C1-10 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl, each exception hydrogen optionally substituted;
- wherein any said optionally substituted alkyl or cycloalkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said optionally substituted aryl or heteroaryl is optionally substituted by one, two or three substituents independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, —C(O)OR11, —(C1-6 alkylene)-OR12, —(C1-6 alkylene)-CN, —(C1-6 alkylene)-C(O)OR11, and —(C1-6 alkylene)-C(O)NRaRb;
- R11 is hydrogen or C1-6 alkyl;
- R12 is hydrogen or C1-6 alkyl; and
- Ra and Rb are each independently hydrogen, C1-6 alkyl, C6-10 aryl, or benzyl.
- In one aspect, the present invention provides Exemplified compounds in Table 1 and Examples in List 1 (below), and pharmaceutically acceptable salts, solvates, or prodrugs thereof.
- In one aspect, the present invention provides a pharmaceutical composition comprising a compound according to any embodiments disclosed here, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.
- In another aspect, the present invention provides a method of treating a disease or disorder associated with hedgehog pathway, the method comprising administering to a subject in need of treatment a therapeutically effective amount of a compound according to any one embodiment disclosed herein, or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutical composition thereof.
- In another aspect, the present invention provides use of the compounds disclosed herein, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treatment of a disease or disorder associated with hedgehog signaling pathway.
- Other aspects or advantages of the present invention will be better appreciated in view of the following detailed description, Examples, and claims.
- The present invention, in one aspect, provides novel heterocyclic compounds, including, including but not limited to indole and benzimidazole compounds, among others, and analogs, especially those characterized by formula (I), useful as therapeutic agents for treatment of diseases or disorders associated with hedgehog signaling pathway based on a new discovery that these compounds can inhibit hedgehog signaling pathway in a mammalian animal.
- In some embodiments, the present invention provides an indole compound of formula (II):
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
-
- R1 is C1-8 alkyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, C6-10 aryl, —(C1-6 alkylene)-C3-6 cycloalkyl, —(C1-6 alkylene)-C6-10 aryl, or —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl);
- R2 is hydrogen, C1-8 alkyl, C6-10 aryl, —C(O)OR8, —C(O)NRaRb, —(C1-6 alkylene)-C6-10 aryl, —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl), —(C1-6 alkylene)-C(O)OR8, or —(C1-6 alkylene)-C(O)NRaRb;
- R3 is hydrogen, halogen, hydroxyl, C1-6 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, or —C(O)OR11;
- R4 is hydrogen, halogen, hydroxyl, or C1-6 alkyl;
- R5 is hydrogen, C1-8 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)nR10 (n is 0, 1, or 2);
- R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
- R9 is hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
- R10 is C1-10 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
- wherein any said alkyl or cycloalkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said aryl or heteroaryl is optionally substituted by one, two or three substituents independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, —C(O)OR11, —(C1-6 alkylene)-OR12—(C1-6 alkylene)-CN, —(C1-6 alkylene)-C(O)OR11, and —(C1-6 alkylene)-C(O)NRaRb;
- R11 is hydrogen or C1-6 alkyl;
- R12 is hydrogen or C1-6 alkyl; and
- Ra and Rb are each independently hydrogen, C1-6 alkyl, C6-10 aryl, or benzyl; provided, however, that the following compounds are excluded:
- In some embodiments of this aspect, the compounds of formula (II) are further defined as follows:
-
- R1 is selected from the group consisting of benzyl, C3-6 cycloalkyl-methyl, 5- or 6-membered heterocyclyl-methyl, and 5 or 6-membered heteroaryl-methyl, each optionally substituted; and
- R2 is C1-6 alkyl, phenyl, or 5-membered heteroaryl, wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of phenyl, 5- or 6-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said heteroaryl or phenyl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, cyano, C1-4 alkyl, C1-4 alkoxy, —C(O)OR11, —(C1-4 alkylene)-OR12, —(C1-4 alkylene)-CN, and —(C1-4 alkylene)-C(O)OR11;
- R3 is hydrogen, C1-6 alkyl, halogen, hydroxyl, C1-4 alkoxy, C3-6 cycloalkyl, or —C(O)OR11;
- R4 is hydrogen, halogen, hydroxyl, or C1-6 alkyl;
- R5 is C1-8 alkyl, phenyl optionally substituted by a C1-6 alkyl, 5- to 6-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)R10 (n is 0, 1, or 2), wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, C(O)NRaRb, and —(C1-8 alkyl)-(C6-10 aryl); and any aryl or heteroaryl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and cyano;
- R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or benzyl;
- R9 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, 5- to 10-membered heteroaryl, or —(C1-4 alkylene)-phenyl;
- R10 is C1-8 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or benzyl;
- R11 is hydrogen or C1-6 alkyl;
- R12 is hydrogen or C1-6 alkyl; and
- Ra and Rb are independently hydrogen or C1-6 alkyl.
- In some embodiments, the present invention provides a benzimidazole compound of formula (III):
-
- or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
- R1 is benzyl with its phenyl group optionally substituted by one or more halogen atoms;
- R2 is C1-6 alkyl optionally substituted by phenyl or —C(O)OR8, wherein phenyl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, C1-6 alkyl, —CN, —C(O)OR11, —(C1-4 alkylene)-OR12, —(C1-4 alkylene)-CN, and —(C1-4 alkylene)-C(O)OR11;
- R3 is halogen, —OR12, or —C(O)OR11;
- R4 is hydrogen;
- R8 at each occurrence is independently hydrogen or C1-4 alkyl;
- R11 is hydrogen or C1-6 alkyl; and
- R12 is hydrogen or C1-6 alkyl;
- provided, however, that the following compounds are excluded:
- In some embodiments, the present invention provides a pyrrolo[2,3-b]pyridine compound of formula (IV):
-
- or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
- R1 is benzyl with its phenyl group optionally substituted by one or more halogen atoms;
- R2 is C1-6 alkyl optionally substituted by phenyl or —C(O)OR8, wherein phenyl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, C1-6 alkyl, —CN, —C(O)OR11, —(C1-4 alkylene)-OR12, —(C1-4 alkylene)-CN, and —(C1-4 alkylene)-C(O)OR11;
- R3 is halogen, C1-6 alkyl, or —OR12;
- R4 is hydrogen;
- R5 is C1-8 alkyl, phenyl optionally substituted by a C1-6 alkyl, 5- to 6-membered heteroaryl, —C(O)OR8, or —C(O)R9, wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, C(O)NRaRb, and —(C1-8 alkyl)-(C6-10 aryl); and any aryl or heteroaryl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and cyano;
- R8 at each occurrence is independently hydrogen or C1-4 alkyl;
- R9 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, 5- to 10-membered heteroaryl, or —(C1-4 alkylene)-phenyl;
- R11 is hydrogen or C1-6 alkyl;
- R12 is hydrogen or C1-6 alkyl; and
- Ra and Rb are independently hydrogen or C1-6 alkyl.
- In some embodiments, the present invention provides a pyrrolo[3,2-b]pyridine compound of formula (V):
-
- or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
- wherein R1 is benzyl with its phenyl group optionally substituted by one or more halogen atoms;
- R2 is C1-6 alkyl optionally substituted by phenyl or —C(O)OR8, wherein phenyl is optionally substituted by one, two, or three substituents independently selected from the group consisting of halogen, C1-6 alkyl, —CN, —C(O)OR11, —(C1-6 alkylene)-OR12, —(C1-6 alkylene)-CN, and —(C1-6 alkylene)-C(O)OR11;
- R3 is halogen, C1-6 alkyl, or —OR12;
- R4 is hydrogen;
- R5 is C1-8 alkyl, phenyl optionally substituted by a C1-6 alkyl, 5- to 6-membered heteroaryl, —C(O)OR8, or —C(O)R9, wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, C(O)NRaRb, and —(C1-8 alkyl)-(C6-10 aryl); and any aryl or heteroaryl is optionally substituted by one, two or three substituents independently selected from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and cyano;
- R8 is independently hydrogen or C1-4 alkyl;
- R9 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, 5- to 10-membered heteroaryl, or —(C1-4 alkylene)-phenyl;
- R11 is hydrogen or C1-6 alkyl; and
- R12 is hydrogen or C1-6 alkyl; and
- Ra and Rb are independently hydrogen or C1-6 alkyl.
- In some embodiments, sometimes preferred, the present invention provides a compound according to any one of Formulas (I), (II), (III), (IV), and (V), wherein (where applicable):
-
- R1 is selected from the group consisting from C1-C6 alkyl,
-
- wherein each X is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or CN; and each R13 is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
- R2 is selected from the group consisting of hydrogen, C1-C6 alkyl,
-
- (Rx is halogen, —(CH2)nCN, or —(CH2)nOR14) wherein each n is 0, 1, or 2; each R14 is independently H or C1-C6 alkyl; and Ra and Rb are independently hydrogen or C1-6 alkyl;
- R3 is selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, C1-C6 haloalkyl, and —C(O)OR15 (R15 is H or C1-C6 alkyl);
- R4 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, hydroxyl, and C1-C6 alkoxy; and/or
- R5 is selected from the group consisting of hydrogen, C1-C8 alkyl, 5-membered heteroaryl,
-
- (R15 is halogen or C1-C6 alkyl),
-
- (R16 is halogen or C1-C6 alkyl),
- and —C(O)—R9, where R9 is C1-C8 alkyl or C3-C6 cycloalkyl;
-
- provided, however, the provisos in any of the embodiments described herein will apply.
- In some embodiments, the present invention provides exemplified compounds in Table 1 and the following list (List 1), and pharmaceutically acceptable salts, solvates, or prodrugs thereof:
- In one aspect, the present invention provides a pharmaceutical composition comprising a compound according to any embodiments disclosed here, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.
- In another aspect, the present invention provides a method of treating a disease or disorder associated with hedgehog pathway, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound according to any one embodiment disclosed herein, or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutical composition thereof.
- In another aspect, the present invention provides use of any of the compounds disclosed herein, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treatment of a disease or disorder associated with hedgehog signaling pathway.
- The diseases and disorders that can be treated using the compounds disclosed herein include, but are not limited to, malignancies associated with hedgehog signaling pathway, for example, medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer, and chondrosarcoma, etc.
- The preferred subjects for treatment include mammalian animals, including humans, horses, dogs, cats, or the like, and more preferably humans.
- Pharmaceutical compositions or formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. Regardless of the route of administration selected, the active ingredient(s) are formulated into pharmaceutically acceptable dosage forms by methods known to those of skill in the art.
- The amount of the active ingredient(s) which will be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration and all of the other factors described above. The amount of the active ingredient(s) which will be combined with a carrier material to produce a single dosage form will generally be that amount of the active ingredient(s) which is the lowest dose effective to produce a therapeutic effect.
- Methods of preparing pharmaceutical formulations or compositions include the step of bringing the active ingredient(s) into association with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly mixing the active ingredient(s) into liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Exemplary, non-limiting examples of formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of the active ingredient(s).
- In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the prodrug(s), active ingredient(s) (in their micronized form) is/are mixed with one or more pharmaceutically-acceptable carriers known to those of skill in the art. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size, and by the use of surfactants.
- These compositions may also contain adjuvants such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like in the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- In some cases, in order to prolong the effect of the active ingredient(s), it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the active ingredient(s) then depends upon its/their rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
- The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a lyophilized condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
- Extemporaneous injection solutions and suspensions maybe prepared from sterile powders, granules and tablets of the type described above.
- Any terms in the present application, unless specifically defined, will take the ordinary meanings as understood by a person of ordinary skill in the art.
- As used herein, the singular forms “a”, “an”, and “the” include plural reference, and vice versa, unless the context clearly dictates otherwise.
- Unless stated otherwise, all aryl, cycloalkyl, heteroaryl, and heterocyclyl groups of the present disclosure may be substituted as described in each of their respective definitions. For example, the aryl part of an arylalkyl group such as benzyl may be substituted as described in the definition of the term “aryl.”
- The term “alkoxy,” as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy group include, but are not limited to, methoxy (CH3O—), ethoxy (CH3CH2O—), or the like.
- The term “alkyl,” as used herein, refers to a group derived from a straight or branched chain saturated hydrocarbon by removal of a hydrogen from one of the saturated carbons. The alkyl group preferably contains from one to ten, sometimes preferably one to six, and sometimes more preferably one to four, carbon atoms. Representative examples of alkyl group include, but are not limited to, methyl, ethyl, isopropyl, and tert-butyl.
- The term “aryl,” as used herein, refers to a group derived from an aromatic carbocycle by removal of a hydrogen atom from an aromatic ring. The aryl group can be monocyclic, bicyclic or polycyclic. Representative examples of aryl groups include phenyl and naphthyl, sometimes more preferably phenyl.
- The term “benzyl,” as used herein, refers to a methyl group on which one of the hydrogen atoms is replaced by a phenyl group, wherein said phenyl group may be substituted by one or more substituents. Representative examples of benzyl group include, but are not limited to, PhCH2—, 4-MeO—C6H4CH2—, and 2,4,6-tri-methyl-C6H4CH2—.
- The term “cyano,” as used herein, refers to —CN.
- The term “cycloalkyl,” as used herein, refers to a group derived from a monocyclic saturated carbocycle, having preferably three to eight, and sometimes more preferably three to six carbon atoms, by removal of a hydrogen atom from the saturated carbocycle. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl.
- The terms “halo” and “halogen,” as used herein, refer to F, Cl, Br, or I.
- The term “haloalkoxy,” as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
- The term “haloalkyl,” as used herein, refers to an alkyl group substituted by at least one halogen atom. The haloalkyl group can be an alkyl group of which all hydrogen atoms are substituted by halogens. Representative examples of haloalkyl include, but are not limited to, trifluoromethyl (CF3—), 2,2,2-trifluoroethyl (CF3CH2—).
- The term “heteroaryl,” as used herein, refers to a group derived from a monocyclic or bicyclic compound comprising at least one aromatic ring comprising one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur, by removal of a hydrogen atom from the aromatic ring. As is well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counterparts. Thus, for the purposes of the invention, a heteroaryl group need only have some degree of aromatic character. Illustrative examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, pyrimidinyl, furyl, thienyl, isoxazolyl, thiazolyl, isoxazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, benzothiazolyl, and benzothienyl.
- The term “heterocyclyl,” as used herein, refers to a group derived from a monocyclic or bicyclic compound comprising at least one nonaromatic ring comprising one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur, by removal of a hydrogen atom from the nonaromatic ring. The heterocyclyl groups of the present disclosure can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom in the group. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, oxazolidinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, thiomorpholinyl, and indolinyl.
- The terms “hydroxy” or “hydroxyl,” as used herein, refer to —OH.
- The term “nitro,” as used herein, refers to —NO2.
- When any group, for example, alkyl, alkenyl, “cycloalkyl,” “aryl,” “heterocyclyl,” or “heteroaryl”, is said to be “optionally substituted,” unless specifically defined, it means that the group is or is not substituted by from one to five, preferably one to three, substituents independently selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, hydroxy, oxo, C1-6 acyl, cyano, nitro, and amino (optionally substituted by one or two C1-6 alkyl groups), or the like, provided that such substitution would not violate the conventional bonding principles known to a person of ordinary skill in the art. When the phrase “optionally substituted” is used before a list of groups, it means that each one of the groups listed may be optionally substituted.
- The compounds of the present disclosure can exist as pharmaceutically acceptable salts or solvates. The term “pharmaceutically acceptable salt,” as used herein, means any non-toxic salt that, upon administration to a recipient, is capable of providing the compounds or the prodrugs of a compound of this invention. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting a suitable nitrogen atom with a suitable acid. Acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, hydrogen bisulfide as well as organic acids, such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid acid, and related inorganic and organic acids.
- Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include, but are not limited to, lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, and N-methylmorpholine.
- The term “solvate,” as used herein, means a physical association of a compound of this invention with one or more, preferably one to three, solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more, preferably one to three, solvent molecules are incorporated in the crystal lattice of the crystalline solid. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
- The term “therapeutically effective amount,” as used herein, refers to the total amount of each active component that is sufficient to show a meaningful patient benefit, e.g., a sustained reduction in viral load. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously.
- The term “pharmaceutically acceptable,” as used herein, refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- The term “patient” includes both human and other mammals.
- The term “treating” refers to: (i) preventing a disease, disorder or condition from occurring in a patient that may be predisposed to the disease, disorder, and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder, or condition, i.e., arresting its development; and (iii) relieving the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and/or condition.
- The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
- Abbreviations or terms used in the following synthetic schemes or processes take the meanings as commonly understood by those skilled in the art.
-
- Synthetic route for example 1
-
- To a solution of THF (500 mL) was added LDA (150 mL, 0.3 mol, 2M in THF). The mixture was cooled to −78° C. Ethyl isobutyrate A1 (33 g, 0.284 mol) was added dropwise and the temperature was kept below −60° C. After addition, the mixture was stirred at −70˜−65° C. for 20 min. 2,3-dichloroprop-1-ene (31 g, 0.279 mol) was added dropwise. The reaction mixture was then allowed to warm to room temperature and stirred for 18 hours. The mixture was quenched with sat. NH4Cl (aq). The organic layer was separated and the aqueous layer was extracted with DCM (2×300 mL). The organic extracts were combined and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give ethyl 4-chloro-2,2-dimethylpent-4-enoate A2 (59 g, 0.279 mol, 93% yield) as brown oil, which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.24-1.28 (m, 9H), 2.65 (s, 2H), 4.15 (q, 4H), 5.13 (s, 1H), 5.24 (s, 1H).
-
- To a mixture of ethyl 4-chloro-2,2-dimethylpent-4-enoate A2 (59 g, 0.279 mol) in EtOH (300 mL) was added water (200 mL). The mixture was cooled ˜5˜0° C. Br2 (48 g, 0.300 mol) was added dropwise. The reaction mixture was stirred for 2 h at room temperature. Water (500 mL) was added and the mixture was extracted with DCM (3×300 mL). The combined extracts were washed with 5% Na2CO3 (aq) and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give ethyl 5-bromo-2,2-dimethyl-4-oxopentanoate A3 (78 g, 0.279 mol, 100% yield) as brown oil, which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.18-1.25 (m, 9H), 2.59 (s, 2H), 3.85 (s, 2H), 4.11 (q, J=7.2 Hz, 2H).
-
- A mixture of ethyl 5-bromo-2,2-dimethyl-4-oxopentanoate A3 (78 g, 0.279 mol) in THF (500 mL) was cooled 0˜5° C. TEA (45 mL, 0.324 mol) and t-BuSH (35 mL, 0.310 mol) was added dropwise. The reaction mixture was stirred for 18 h at room temperature. PE (300 mL) was added and the reaction mixture was filtered. The filtrate was evaporated and the residue was purified by flash column chromatography on silica gel (PE:EtOAc=20:1) to give ethyl-5-(tert-butylthio)-2,2-dimethyl-4-oxopentanoate A4 (71.2 g, 0.273 mol, 98% yield) as brown oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.24-1.20 (m, 9H), 1.31 (s, 9H), 2.94 (s, 2H), 3.27 (s, 2H), 4.11 (q, J=6.8 Hz, 2H).
-
- To a mixture of (4-isopropylphenyl)hydrazine hydrochloride B1 (5.8 g, 31.1.0 mmol) and 1-chloro-4-(chloromethyl)benzene (5.0 g, 31.1 mmol) in tolune (100 mL) was added TEA (9 mL, 64.7 mmol), followed by TBAB (100 mg, 0.31 mmol). The mixture was heated to reflux (110° C., oil bath) for 4 h and the reaction mixture was cooled to room temperature. The mixture was concentrated and the residue was diluted in EtOAc (15 mL) and PE (100 mL). The mixture was filtered and to the filtrate was added 6.0 N HCl in 1,4-dioxane (10 mL). The mixture was stirred for 2 h at room temperature and filtered to give 1-(4-chlorobenzyl)-1-(4-isopropylphenyl)hydrazine (HCl salt) B2 (6.5 g, 23.7 mmol, 64% yield) as a white solid.
-
- To a mixture of 1-(4-chlorobenzyl)-1-(4-isopropylphenyl)hydrazine (HCl salt) B2 (3.2 g, 10.3 mmol) and ethyl 5-(tert-butylthio)-2,2-dimethyl-4-oxopentanoate A4 (3.0 g, 11.5 mmol) in AcOH (25 mL) was added tolune (50 mL) and AcONa (1.0 g, 12.2 mmol). The reaction mixture was stirred for 72 h at room temperature. The mixture was concentrated and the residue was purified by column chromatography on silica gel (eluent: EA:PE=1:30) to give ethyl 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoateB3 (2.7 g, 5.4 mmol, 52% yield) as yellow solid. LCMS (ESI): m/z 500.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.15-1.09 (m, 9H), 1.19 (s, 9H), 1.22 (d, J=7.2 Hz, 6H), 2.85-3.00 (m, 1H), 3.23 (s, 2H), 4.04 (q, J=7.2 Hz, 2H), 5.46 (s, 2H), 6.86 (d, J=8.8 Hz, 2H), 6.987 (dd, J=8.8, 1.6 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 7.34-7.32 (d, J=8.4 Hz, 2H), 7.47 (s, 1H).
-
- To a mixture of ethyl 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isop ropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B3 (1.0 g, 2.0 mmol) in DCM (50 mL) was cooled to 0˜5° C. in an ice bath. AlCl3 (2.0 g, 15.0 mmol) was added in portions. After addition, the mixture was stirred for 18 h at room temperature. The mixture was quenched with Sat. NH4Cl (aq). The organic layer was separated, dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by preparation TLC (PE:EA=10:1) to give ethyl 3-(1-(4-ch lorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate (B4) (620 mg, 1.5 mmol, 75% yield) as brown oil. LCMS (ESI): m/z 412.4[M+H]+.
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B4 (500 mg, 1.21 mmol) in DCE (30 mL) was added AlCl3 (600 mg, 4.49 mmol) and cyclobutanecarbonyl chloride (500 mg, 4.22 mmol). The mixture was heated to reflux for 4 h. The mixture was quenched with water (50 mL). The organic layer was separated, dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by preparation TLC (PE:EA=10:1) to give ethyl 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate (2) (170 mg, 0.34 mmol, 28% yield) as yellow oil. LCMS (ESI): m/z 494.3[M+Na]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.06 (t, J=6.8 Hz, 3H), 1.14 (s, 6H), 1.22 (d, J=6.8 Hz, 6H), 1.85-1.90 (m, 1H), 1.95-1.99 (m, 1H), 2.35-2.25 (m, 4H), 2.92-2.97 (m, 1H), 3.55 (s, 2H), 3.88-4.01 (m, 3H), 5.25 (s, 2H), 6.70 (d, J=7.6 Hz, 2H), 6.96 (s, 2H), 7.11 (d, J=7.2 Hz, 2H), 7.26 (s, 1H), 7.56 (s, 1H).
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate 2 (50 mg, 0.10 mmol) in THF (1 mL) was added LiOH·H2O (10 mg, 0.24 mmol) and water (1 mL). The mixture was heated to 65° C. for 18 h. After cooled to room temperature, the mixture was concentrated and the residue was purified by pre-HPLC to give 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid 1 (22 mg, 0.047 mmol, 47% yield) as white solid. LCMS (ESI): m/z 466.3[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.12 (s, 6H), 1.26 (d, J=6.8 Hz, 6H), 1.85-1.90 (m, 1H), 1.98-2.05 (m, 1H), 2.20-2.35 (m, 4H), 2.99-3.05 (m, 1H), 3.59 (s, 2H), 4.03-4.08 (m, 1H), 5.49 (s, 2H), 6.91 (d, J=7.6 Hz, 2H), 7.06 (d, J=8.4 Hz, 1H), 7.30-7.36 (m, 3H), 7.63 (s, 1H), 12.49 (br s, 1H).
-
- The compound 10 was prepared by the method similar to the compound ethyl 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate (compound 2) in the step 1.7, but using isobutyryl chloride. LCMS (ESI): m/z 482.4[M+Na]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.55 (t, J=7.2 Hz, 3H), 1.23 (s, 6H), 1.31 (t, J=6.0 Hz, 12H), 3.08-3.00 (m, 1H), 3.70-2.55 (m, 3H), 4.03-3.98 (m, 2H), 5.36 (s, 2H), 6.80 (d, J=8.0 Hz, 2H), 7.06 (s, 2H), 7.21 (d, J=8.0 Hz, 2H), 7.71 (s, 1H).
-
- The compound 9 was prepared by the method similar to the example 1, but using ethyl 3-(1-(4-chlorobenzyl)-3-isobutyryl-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate in the step 1.8. LCMS (ESI): m/z 454.4[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.10 (s, 6H), 1.18 (d, J=6.8 Hz, 6H), 1.26 (d, J=6.8 Hz, 6H), 3.05-2.98 (m, 1H), 3.60-3.53 (m, 3H), 5.51 (s, 2H), 6.92 (d, J=8.0 Hz, 2H), 7.08 (d, J=8.8 Hz, 2H), 7.36 (d, J=8.4 Hz, 2H), 7.67 (s, 1H), 12.42 (brs, 1H).
-
- Synthetic route for example 3
-
- To a mixture of 2,2-dimethylpropane-1-thiol (210 mg, 2.0 mmol) in toluene (8 mL)/Et2O (15 mL) was added TEA (607 mg, 6.0 mmol). Ethyl 5-bromo-2,2-dimethyl-4-oxopentanoate (552.2 mg, 2.2 mmol) was then added dropwise. The reaction mixture was stirred for 18 h at room temperature. The mixture was concentrated and the residue was re-dissolved in EtOAc (30 mL) and washed with water (20 mL), followed by brine (20 mL). The organics were dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The crude product was purified by pre-TLC (PE:EA=20:1) to give ethyl 2,2-dimethyl-5-(neopentylthio)-4-oxopentanoate (220 mg, 0.8 mmol, 39.8% yield) as yellow oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 4.14-4.12 (q, 2H), 3.46-3.55 (m, 2H), 3.14 (s, 2H), 2.41 (s, 2H), 1.26 (s, 6H), 0.97 (s, 9H), 0.91-0.93 (m, 3H).
-
- To a mixture of 1-(4-chlorobenzyl)-1-(4-isopropylphenyl)hydrazine (HCl salt)(360.5 mg, 1.31 mmol) and 2,2-dimethyl-5-(neopentylthio)-4-oxopentanoate (300 mg, 1.09 mmol) in AcOH (5 mL) was added tolune (15 mL) and AcONa (322 mg, 3.28 mmol). The reaction mixture was stirred for 16 h at 20° C. The mixture was concentrated and the residue was re-dissolved in EtOAc (50 mL). The resulting solution was washed with water (15 mL), followed by brine (15 mL), dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The crude product was purified by pre-TLC (PE:EA=20:1) to give ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate (160 mg, 0.31 mmol, 28.5% yield) as yellow oil. LCMS (ESI): m/z 514.4 [M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.05 (s, 9H), 1.19 (t, J=14.0 Hz, 3H), 1.24 (s, 6H), 1.32 (d, J=7.2 Hz, 6H), 2.71 (s, 2H), 3.02-3.05 (m, 1H), 3.22 (s, 2H), 4.02-4.08 (m, 2H), 5.30 (s, 2H), 6.73 (d, J=8.4 Hz, 2H), 7.02 (s, 2H), 7.18 (d, J=8.4 Hz, 2H), 7.58 (s, 1H).
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate (50 mg, 0.098 mmol) in THF (2 mL)/MeOH (3 mL)/H2O (2 mL) was added LiOH·H2O (16.3 mg, 0.39 mmol). The reaction mixture was stirred for 16 h at 60° C. After cooled to room temperature, the mixture was concentrated and the residue was diluted with water (5 mL). The solution was acidified with 2.0 N HCl (aq) to pH=6. The mixture was extracted with EtOAc (2×15 mL). The extracts were combined and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentr-ated. The residue was purified by prep-HPLC to give 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoic acid (25 mg, 0.05 mmol, 52.9% yield) as yellow solid. LCMS (ESI): m/z 486.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.99 (s, 9H), 1.14 (s, 6H), 1.24 (d, J=7.2 Hz, 6H), 2.65 (s, 2H), 2.96-2.99 (m, 1H), 3.16 (s, 2H), 5.43 (s, 2H), 6.82 (d, J=8.0 Hz, 2H), 7.01 (d, J=9.2 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 7.42 (s, 1H), 12.47 (s, 1H).
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate (250 mg, 0.49 mmol) in DCM (10 mL) was added m-CPBA (108.6 mg, 0.54 mmol) at −20° C. The reaction mixture was stirred for 2 h at −20° C. The mixture was then washed with NaHCO3 (aq), dried over anhydrous Na2SO4 and concentrated. The residue was purified by pre-HPLC to give ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylsulfinyl)-1H-indol-2-yl)-2,2-dimethylpropanoate (108 mg, 0.2 mmol, 41.9% yield) as a yellow oil. LCMS (ESI): m/z 530.3 [M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.17-1.21 (m, 12H), 1.27-1.32 (m, 12H), 2.99-3.04 (m, 3H), 3.24 (d, J=2.0 Hz, 2H), 3.73 (d, J=13.2 Hz, 2H), 4.01-4.05 (m, 2H), 5.32 (s, 2H), 6.80 (d, J=8.4 Hz, 2H), 7.05-7.09 (m, 2H), 7.11 (d, J=8.0 Hz, 2H), 7.22 (d, J=8.4 Hz, 2H), 7.98 (s, 1H).
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylsulfinyl)-1H-indol-2-yl)-2,2-dimethylpropanoate (100 mg, 0.19 mmol) in in THF (3 mL)/MeOH (3 mL)/H2O (3 mL) was added LiOH·H2O (31.7 mg, 0.75 mmol). The mixture was stirred for 16 h at 60° C. and then concentrated. The residue was diluted with water (5 mL). The solution was acidified with 1.0 N HCl (aq) to pH=6. The mixture was extracted with EtOAc (2×25 mL). The organic extracts were combined and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by prep-HPLC to give 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylsulfinyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid (40 mg, 0.08 mmol, 42.2% yield) as light yellow solid. LCMS (ESI): m/z 502.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.14 (s, 9H), 1.18 (d, J=12.0 Hz, 6H), 1.25 (d, J=6.8 Hz, 6H), 2.87 (d, J=13.2 Hz, 1H), 2.99 (m, 1H), 3.18 (d, J=4.8 Hz, 2H), 3.57 (d, J=13.2 Hz, 1H), 5.47 (s, 2H), 6.93 (d, J=8.8 Hz, 2H), 7.09-7.11 (m, 2H), 7.32-7.36 (m, 3H), 7.84 (s, 1H).
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate (250 mg, 0.49 mmol) in DCM (10 mL) was added m-CPBA (296 mg, 1.46 mmol) at 15° C. The reaction mixture was stirred for 16 h at 15° C. The mixture was treated with Na2SO3 (aq) and extracted with DCM (50 mL). The organic extract was washed with water (15 mL), followed by brine (15 mL), dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The crude product was purified by pre-HPLC to give ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylsulfonyl)-1H-indol-2-yl)-2,2-dimethylpropanoate (100 mg, 0.18 mmol, 37.7% yield) as yellow oil. LCMS (ESI): m/z 546.3 [M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.15 (t, J=14.0 Hz, 3H), 1.22 (s, 9H), 1.30-1.32 (m, 12H), 2.71 (s, 2H), 3.02-3.06 (m, 1H), 3.18 (s, 2H), 3.57 (s, 2H), 3.95-4.00 (m, 2H), 5.34 (s, 2H), 6.81 (d, J=8.4 Hz, 2H), 7.04 (d, J=8.4 Hz, 2H), 7.11 (d, J=8.0 Hz, 2H), 7.23 (d, J=8.8 Hz, 2H), 7.78 (s, 1H).
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylsulfinyl)-1H-indol-2-yl)-2,2-dimethylpropanoate (100 mg, 0.19 mmol) in THF (3 mL)/MeOH (3 mL)/H2O (3 mL) was added LiOH·H2O (31.7 mg, 0.75 mmol). The reaction mixture was stirred for 16 h at 60° C. and then concentrated. The residue was diluted with water (5 mL). The resulting solution was acidified with 1.0 N HCl (aq) to pH=6. The mixture was extracted with EtOAc (2×25 mL). The organic extracts were combined and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by pre-HPLC to give 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylsulfonyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid (40 mg, 0.08 mmol, 42.2% yield) as light yellow solid. LCMS (ESI): m/z 518.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.11 (s, 9H), 1.18 (s, 6H), 1.24 (d, J=6.8 Hz, 6H), 2.98-3.01 (m, 1H), 3.20 (s, 2H), 3.47 (s, 2H), 5.49 (s, 2H), 6.96 (d, J=8.0 Hz, 2H), 7.14 (d, J=8.0 Hz, 2H), 7.36 (d, J=8.0 Hz, 2H), 7.62 (s, 1H), 12.60 (s, 1H).
-
- Synthetic route for example 4
-
- A solution of ethyl acetate (8 g, 90.9 mmol) in THF (150 mL) was cooled to −78° C. LDA (40 mL, 80 mmol, 2M in THF) was added dropwise. The mixture was stirred at −78° C. for 1 h. 2,3-dibromoprop-1-ene (13.5 g, 67.5 mmol) was added dropwise. The reaction mixture was then allowed to warm to −30° C. and stirred for 2 h. The mixture was quenched with water (300 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3×150 mL). The combined organics were dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give ethyl 4-bromopent-4-enoate C2 (22 g) as yellow oil which was directly used in the next step without further purification.
-
- To a mixture of crude ethyl 4-bromopent-4-enoate (1 g, 4.83 mmol) in ACN (10 mL) was added water (2 mL) and NBS (1 g, 5.62 mmol). The reaction mixture was stirred for 3 h at room temperature and then concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give ethyl 5-bromo-4-oxopentanoate (C3) (180 mg, 0.81 mmol, 55% yield) as yellow oil.
-
- A mixture of ethyl 5-bromo-4-oxopentanoate (5.5 g, 24.7 mmol) in THF (50 mL) was cooled to 0˜5° C. TEA (3.5 g, 34.6 mmol) and t-BuSH (3.5 g, 38.9 mmol) were added dropwise. The mixture was stirred for 18 h at room temperature. PE (300 mL) was added and the reaction mixture was filtered. The filtrate was evaporated and the residue was purified by flash column chromatography on silica gel (PE:EA=20:1) to give ethyl 5-(tert-butylthio)-4-oxopentanoate(C4) (2.0 g, 8.6 mmol, 35% yield) as yellow oil.
-
- The compound 12 was prepared by the method similar to the compound ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate in the step 3.2, but using ethyl 5-(tert-butylthio)-4-oxopentanoate (C4). LCMS (ESI): m/z 472.3[M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.23 (t, J=7.2 Hz, 3H), 1.35-1.29 (m, 15H), 2.46 (t, J=8.0 Hz, 2H), 3.04-3.00 (m, 1H), 3.23 (t, J=8.0 Hz, 2H), 5.36 (s, 2H), 6.90 (d, J=8.4 Hz, 2H), 7.09-7.02 (m, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.62 (s, 1H).
-
- The compound 11 was prepared by the method similar to the compound ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate in the step 3.3, but using compound ethyl 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate. LCMS (ESI): m/z 444.2[M+H]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.25-1.22 (m, 15H), 2.36 (t, J=8.4 Hz, 2H), 2.98-2.94 (m, 1H), 3.14 (t, J=7.6 Hz, 2H), 5.51 (s, 2H), 7.02-6.94 (m, 3H), 7.26 (d, J=8.4 Hz, 1H), 7.39 (d, J=8.0 Hz, 2H), 7.46 (s, 1H), 12.28 (brs, 1H).
-
- Synthetic route for example 5
-
- A mixture of methyl 4-chloro-3-oxobutanoate (1.0 g, 6.62 mmol) in THF (20 mL) was cooled 0˜5° C. TEA (2.0 g, 19.9 mmol) was then added, followed by t-BuSH (1.7 g, 13.4 mmol) dropwise. The reaction mixture was stirred for 18 h at room temperature. PE (300 mL) was added and the mixture was filtered. The filtrate was concentrated and the residue was purified by flash column chromatography on silica gel (PE:EA=20:1) to give methyl 4-(tert-butylthio)-3-oxobutanoate (1.2 g, 5.88 mmol, 89% yield) as yellow oil.
-
- The compound 14 was prepared by the method similar with ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-3-(neopentylthio)-1H-indol-2-yl)-2,2-dimethylpropanoate (compound 4) in step 3.2, but using methyl 4-(tert-butylthio)-3-oxobutanoate(C4′). LCMS (ESI): m/z 444.3[M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.65 (s, 1H), 7.22-7.25 (m, 2H), 7.08-7.11 (t, J=11.6 Hz, 2H), 6.88-6.90 (d, J=8.4 Hz, 2H), 5.35 (s, 2H), 4.02 (s, 2H), 3.55 (s, 3H), 3.01-3.04 (m, 1H), 1.29-1.31 (d, J=8.0 Hz, 15H).
-
- The compound 13 was prepared by the method similar to the compound 1 in the step 1.8, but using compound methyl 2-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)acetate (compound 14). LCMS (ESI): m/z 430.3[M+H]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 12.7(brs, 1H), 7.48 (s, 1H), 7.35 (d, J=8.0 Hz, 2H), 7.23 (d, J=8.4 Hz, 2H), 7.02 (d, J=8.4 Hz, 3H), 5.45 (s, 2H), 3.97 (s, 2H), 2.50 (m, 1H), 1.22-1.24 (t, J=6.8 Hz, 15H).
-
- Synthetic route for example 6
-
- To a mixture of 4,4-dimethylpentan-2-one (1.2 g, 12.3 mmol) in MeOH (2.5 mL) was added Br2 (1.8 g, 11.3 mmol) in an ice-bath. After addition, the mixture was stirred at room temperature for 30 min and then quenched with water (30 mL). The mixture was extracted with DCM (2×20 mL). The organic extracts were combined and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give 1-bromo-4,4-dimethylpentan-2-one C3″ (1.6 g, 8.3 mmol, 73% yield) as yellow oil used as the intermediate without further purification.
-
- To a mixture of 1-bromo-4,4-dimethylpentan-2-one (C3″) (1.6 g, 8.3 mmol) in THF (50 mL) was added TEA (2.8 mL, 20.2 mmol) and t-BuSH (1.3 mL, 11.5 mmol). The reaction mixture was stirred for 18 h at room temperature. It was filtered and the filtrate was concentrated to give 1-(tert-butylthio)-4,4-dimethylpentan-2-one (C4″) (1.4 g, 6.9 mmol, 84% yield) as yellow oil used as the intermediate without further purification.
-
- To a mixture of 1-(tert-butylthio)-4,4-dimethylpentan-2-one (500 mg, 2.48 mmol) and 1-(4-chlorobenzyl)-1-(4-isopropylphenyl)hydrazine hydrochloride (750 mg, 2.41 mmol) in AcOH (15 mL) was added toluene (25 mL) and AcONa (220 mg, 2.68 mol). The reaction mixture was stirred for 30 hours at room temperature and then concentrated. The residue was purified by flash column chromatography on silica gel (PE:EA=20:1) to give 3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-2-neopentyl-1H-indole (122 mg, 0.28 mmol, 11% yield) as white solid. LCMS (ESI): m/z 442.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.99 (s, 9H), 1.26 (s, 9H), 1.30 (d, J=7.2 Hz, 6H), 2.88 (br s, 2H), 3.05-2.97 (m, 1H), 5.39 (s, 2H), 6.74 (d, J=8.4 Hz, 2H), 6.99 (d, J=8.4, 1.2 Hz, 1H), 7.04 (d, J=8.0 Hz, 2H), 7.20 (d, J=8.4 Hz, 2H), 7.64 (s, 1H).
-
- Synthetic route for example 7
-
- To a solution of tert-butyl (5-bromopyridin-2-yl)carbamate (5.40 g, 20 mmol) in 1,4-dioxane (100 mL), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (3.40 g, 20 mmol), PdCl2(dppf) (1.45 g, 2 mmol) and Na2CO3 (2.12 g, 20 mmol) were added. The mixture was stirred overnight at 110° C. under N2. After cooled to the room temperature, it was filtered, and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give tert-butyl (5-(prop-1-en-2-yl)pyridin-2-yl)carbamate (2.57 g, 11 mmol, 55% yield) as oil. LCMS (ESI): m/z 235.4[M+1]+.
-
- To a solution of tert-butyl (5-(prop-1-en-2-yl)pyridin-2-yl)carbamate (2.57 g, 11 mmol) in MeOH (30 mL), Pd/C (300 mg, 0.14 mmol) was added, the mixture was stirred overnight at 25° C. under N2. It was filtrated, and the filtrate was concentrated to give tert-butyl (5-isopro pylpyridin-2-yl) carbamate (2.36 g, 10 mmol, 90.9% yield) as oil used as the intermediate without further purification. LCMS (ESI): m/z 237.2[M+1]+.
-
- A solution of tert-butyl (5-isopropylpyridin-2-yl)carbamate (2.36 g, 10 mmol) in 6N HCl/MeOH (50 mL) was stirred for 2 h. It was concentrated and H2O (40 mL) was added. The mixture was basified with NaHCO3 to PH=8. The mixture was extracted with DCM (3×20 mL). The organic extracts were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated to give 5-isopropylpyridin-2-amine (1.20 g, 8.8 mmol, 88% yield) as oil used as the intermediate without further purification. LCMS (ESI): m/z 137.4[M+1]+.
-
- To a solution of 5-isopropylpyridin-2-amine (1.20 g, 8.8 mmol) in DCM (50 mL), Br2 (1.40 g, 8.8 mmol) was added dropwise. The mixture was stirred for 1.0 hour at 10° C. The mixture was washed with NaHCO3 (2×60 mL) and brine (40 mL), dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=5:1) to give 3-bromo-5-isopropylpyridin-2-amine (950 mg, 4.4 mmol, 50% yield) as oil. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.21 (d, J=6.8 Hz, 6H), 2.80 (m, 1H), 4.81 (s, 2H), 7.53 (d, J=1.6 Hz, 1H), 7.88 (d, J=1.6 Hz, 1H).
-
- To a mixture of 3-bromo-5-isopropylpyridin-2-amine (500 mg, 2.33 mmol) and ethyl 2,2-dimethylpent-4-ynoate (770 mg. 5 mmol,) in toluene (5 mL), PdCl2(dppf) (182 mg, 0.25 mmol) and Et3N (378 mg, 3.75 mmol) was added. The reaction mixture was irrited via microwave reactor for 20 min at 140° C. under N2. The mixture was concentrated and the residue was purified by prep TLC (PE:EA=3:1) to give ethyl 5-(2-amino-5-isopropylpyridin-3-yl)-2,2-dimethylpent-4-ynoate (210 mg, 0.73 mmol, 30.4% yield) as yellow solid. LCMS (ESI): m/z 289.4[M+1]+.
-
- To a mixture of ethyl 5-(2-amino-5-isopropylpyridin-3-yl)-2,2-dimethylpent-4-ynoate (210 mg, 0.73 mmol) in THF (10 mL), t-BuOK (178 mg, 1.5 mmol) was added. The reaction mixture was heated to 60° C. for 1.0 hour. The mixture was concentrated and EtOH (10 mL) and H2SO4 (296 mg, 3 mmol) were added. The mixture was heated overnight at 80° c. The mixture was concentrated, and H2O (20 mL) was added. The mixture was neutralized with NaHCO3. It was extracted with DCM (3×20 mL). The organic extracts were washed with NaHCO3 (20 mL) and brine (20 mL), dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=3:1) to give ethyl 3-(5-isopropyl-1H-pyrrolo [2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (165 mg, 0.57 mmol, 78.4% yield) as oil. LCMS (ESI): m/z 289.4[M+1]+.
-
- To a mixture of ethyl 3-(5-isopropyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (165 mg, 0.57 mmol) in DMF (3.0 mL), 1-chloro-4-(chloromethyl)benzene (92 mg, 0.57 mmol) and Cs2CO3 (370 mg, 1.14 mmol) were added. The mixture was stirred overnight at 60° C. H2O (15 mL) was added and the mixture was extracted with DCM (3×10 mL). The organic extracts were combined and washed with brine (2×10 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-1H-pyrrolo [2,3-b]pyridin-2-yl)-2,2-dimethy lpropanoate (140 mg, 0.34 mmol, 59.6% yield) as yellow solid. LCMS (ESI): m/z 413.3[M+1]+.
-
- To a solution of ethyl 3-(1-(4-chlorobenzyl)-5-isopropyl-1H-pyrrolo [2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (120 mg, 0.29 mmol) in DCE (5 ml), AlCl3 (193 mg, 1.45 mmol) was added under N2. The mixture was heated to 80° C., then cyclobutanecarbonyl chloride (171 mg, 1.45 mmol) was added dropwise. After addition, the mixture was stirred overnight at 80° C., and then poured into ice slowly. 1.0 N HCl (10 mL) was added and the mixture extracted with CH2Cl2 (2×15 mL). The organic extracts were combined and washed with water (2×15 mL), dried (MgSO4), and concentrated, purified by column chromatography on silica gel (PE:EA=10:1) to give ethyl 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (72 mg, 0.14 mmol, 50% yield) as yellow solid. LCMS (ESI): m/z 495.3[M+1]+.
-
- To a mixture of ethyl3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (72 mg, 0.14 mmol) in THF (5 mL) was added LiOH·H2O (50 mg, 1.19 mmol) and water (1.0 mL). The mixture was heated to 60° C. for 18 hours and concentrated. The residue was purified by preparation HPLC to give 3-(1-(4-chlorobenzyl)-3-(cyclobutanecarbonyl)-5-isopropyl-1H-pyrrolo-[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoic acid (16) (14 mg, 0.030 mmol, 21% yield) as white solid. LCMS (ESI): m/z 467.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ ppm 1.10 (s, 6H), 1.32-1.27 (d, J=6.8 Hz, 6H), 1.79 (m, 1H), 2.03-2.01 (m, 1H), 2.49-2.24 (m, 4H), 3.12-3.09 (m, 1H), 3.50 (s, 2H), 4.10-4.05 (m, 1H), 5.57 (s, 2H), 6.94 (d, J=8.8 Hz, 2H), 7.35 (d, J=8.4 Hz, 2H), 8.04 (d, J=2.0 Hz, 1H), 8.21 (d, J=1.6 Hz, 1H), 12.50 (s, 1H).
-
- Synthetic route for example 8
-
- To a solution of 5-methoxypyridin-2-amine (7.0 g, 56 mmol) in AcOH (50 mL), Br2 (9.0 g, 56 mmol) was added dropwise at 0° C. The mixture was stirred at 10° C. for 1.0 hour. H2O (200 ml) was added and the mixture was extracted with DCM (3×60 ml). The organic extracts were combined and washed with NaHCO3 (2×60 mL) and brine (40 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give 3-bromo-5-methoxypyridin-2-amine (4.2 g, 20 mmol, 35% yield) as yellow solid. LCMS (ESI): m/z 203.0 [M+1]+.
-
- To a mixture of 3-bromo-5-methoxypyridin-2-amine (500 mg, 2.5 mmol) and ethyl 2,2-dimethylpent-4-ynoate (770 mg. 5 mmol) in toluene (5 mL), PdCl2(dppf) (182 mg, 0.25 mmol) and Et3N (378 mg, 3.75 mmol) were added, the mixture was irritated via microwave reactor for 20 min at 140° C. under N2. The mixture was concentrated and the residue was purified by TLC (PE:EA=5:1) to give ethyl 5-(2-amino-5-methoxypyridin-3-yl)-2,2-dimethylpent-4-ynoate (210 mg, 0.76 mmol, 30.4% yield) as yellow solid. LCMS (ESI): m/z 277.3 [M+1]+.
-
- To a mixture of ethyl 5-(2-amino-5-methoxypyridin-3-yl)-2,2-dimethylpent-4-ynoate (1.20 g, 4.3 mmol) in THF (20 mL), t-BuOK (490 mg, 4.3 mmol) was added. The mixture was heated to 60° c. for 1.0 hour. The mixture was concentrated. EtOH (20 ml) and H2SO4 (1.05 g, 10.8 mmol) were added, and the mixture was heated to 80° c. overnight. The mixture was concentrate. H2O (20 mL) was added and the mixture was neutralized with NaHCO3, extracted with DCM (3×20 mL). The organic extracts were combined and washed with NaHCO3 (20 ml) and brine (20 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give ethyl3-(5-methoxy-1H-pyrrolo [2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (910 mg, 3.3 mmol, 76.7% yield) as oil. LCMS (ESI): m/z 277.4 [M+1]+.
-
- To a mixture of ethyl 3-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (850 mg, 3.19 mmol) in DMF (10 mL), 1-chloro-4-(chloromethyl) benzene (615 mg, 3.8 mmol) and Cs2CO3 (2.08 g, 6.4 mmol) were added, the mixture was heated to 60° C. overnight. H2O (100 mL) was added, and the mixture was extracted with DCM (3×30 mL). The organic extracts were combined and washed with brine (2×30 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silicagel (PE:EA=5:1) to give ethyl3-(1-(4-chlorobenzyl)-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (810 mg, 2.0 mmol, 62.5% yield) as yellow solid. LCMS (ESI): m/z 401.3 [M+1]+.
-
- To a mixture of thyl 3-(1-(4-chlorobenzyl)-5-methoxy-1H-pyrrolo [2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (400 mg, 1 mmol) in acetonitrile (10 mL), NIS (270 ng, 1.2 mmol) was added. The mixture was stirred for 2.0 hours at 10° C. The mixture was concenrated and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give ethyl 3-(1-(4-chlorobenzyl)-3-iodo-5-methoxy-1H-pyrrolo[2,3-b] pyridin-2-yl)-2,2-dimethylpropanoate (410 mg, 0.78 mmol, 78% yield) as yellow solid. LCMS (ESI): m/z 527.2 [M+1]+.
-
- To a mixture of ethyl 3-(1-(4-chlorobenzyl)-3-iodo-5-methoxy-1H-pyrrolo[2,3-b] pyridin-2-yl)-2,2-dimethylpropanoate (410 mg, 0.78 mmol) in toluene (5 mL), t-BuOK (240 mg, 2 mmol), 2-methylpropane-2-thiol (270 mg, 3.0 mmol), Pd2(dba)3 (91 mg, 0.1 mmol) and Tricyclohexylphosphoniuim tetrafluoroborate (36.8 mg, 0.1 mmol) were added. The mixture was irritated via microwave reactor at 140° C. under N2. After cooled to room temperature, the mixture was concentrated. The residue was purified by preparation TLC (PE:EA=5:1) to give ethyl3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (210 mg, 0.43 mmol, 55% yield) as yellow solid. LCMS (ESI): m/z 489.3[M+1]+. 1HNMR (400 MHz, CDCl3): δ ppm 1.18-1.15 (m, 3H), 1.21 (s, 6H), 1.23 (s, 9H), 3.18 (s, 2H), 3.90 (s, 3H), 4.12 (m, 2H), 5.54 (s, 2H), 6.76 (d, J=8.4 Hz, 2H), 7.19 (d, J=8.4 Hz, 2H), 7.53 (d, J=2.4 Hz, 1H), 8.04 (d, J=2.8 Hz, 1H).
-
- To a mixture of ethyl 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoate (50 mg, 0.1 mmol) in THF (5 mL) was added LiOH·H2O (50 mg, 1.19 mmol) and water (1 mL). The mixture was heated to 60° C. for 18 hours. After cooled to room temperature, the mixture was concentrated. The residue was purified by preparation HPLC to give 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2,2-dimethylpropanoic acid (14 mg, 0.030 mmol, 32% yield) as white solid. LCMS (ESI): m/z 461.2 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.10 (s, 6H), 1.18 (s, 9H), 3.14 (s, 2H), 3.85 (s2, 3H), 5.56 (s, 2H), 6.84 (d, J=8.0 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 7.50 (d, J=2.4 Hz, 1H), 8.00 (d, J=2.4 Hz, 1H), 12.51 (s, 1H).
-
- Synthetic route for example 9
-
- To a solution of ethyl 3-(1-(4-chlorobenzyl)-5-hydroxy-1H-indol-2-yl)-2,2-dimethylpropanoate (2.0 g, 5.2 mmol) in DMF (50 mL) were added Cs2CO3 (5.1 g, 15.6 mmol), (bromomethyl)benzene (1.15 g, 6.8 mmol) and (n-Bu)4NI (0.19 g, 0.52 mmol) at room temperature. After addition, the reaction mixture was stirred for 15 hours at room temperature. The mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give ethyl 3-(5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indol-2-yl)-2,2-dimethylpropanoate (2.3 g, 4.8 mmol, 92% yield) as yellow oil. LCMS (ESI): m/z 476.3[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.20 (t, J=7.2 Hz, 3H), 1.25 (s, 6H), 2.92 (s, 2H), 4.11 (q, J=6.4 Hz, 2H), 5.08 (s, 2H), 5.29 (s, 2H), 6.78-6.85 (m, 3H), 7.00 (d, J=8.8 Hz, 1H), 7.11 (d, J=2 Hz, 2H), 7.21 (d, J=8.4 Hz, 1H), 7.31-7.33 (m, 1H), 7.36-7.40 (m, 2H), 7.45-7.47 (m, 2H).
-
- To a solution of ethyl 3-(5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indol-2-yl)-2,2-dimethylpropanoate (2.9 g, 6.1 mmol) in DCM (200 mL) were added AlCl3 (4.1 g, 30.5 mmol) and 3,3-dimethylbutanoyl chloride (4.1 g, 30.5 mmol) at −70° C. After addition, the reaction mixture was stirred for 30 min at −70° C. The mixture was acidified with 1.0 N HCl (aq) to pH=4 and then extracted with DCM (2×10 mL). The organic extracts were combined and washed with brine (2×10 mL), dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give 1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-2-(3-ethoxy-2,2-dimethyl-3-oxopropyl)-1H-indol-5-yl3, 3-dimethylbutanoate (3.5 g, 6 mmol, 98% yield) as yellow solid used as the intermediate without further purification. LCMS (ESI): m/z 582[M+1]+.
-
- To a solution of 1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-2-(3-ethoxy-2,2-dimethyl-3-oxopropyl)-1H-indol-5-yl 3,3-dimethylbutanoate (3.5 g, 6 mmol) in THF (50 mL) and MeOH (50 mL) was added water (100 mL) and LiOH·H2O (2.5 g, 60 mmol) at room temperature. After addition, the reaction mixture was stirred at 60° C. for 15 h. The mixture was acidified with 1.0 N HCl (aq) to pH=4.0. It was then extracted with DCM (2×100 mL). The organic extracts were combined and washed with brine (2×100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=1:1) to give 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-hydroxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (2.2 g, 4.8 mmol, 80% yield) as white solid. LCMS (ESI): m/z 456.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.08 (s, 9H), 1.12 (s, 6H), 2.86 (s, 2H), 3.52 (s, 2H), 5.45 (s, 2H), 6.64 (d, J=7.2 Hz, 1H), 6.88 (d, J=8.0 Hz, 2H), 7.20 (d, J=8.8 Hz, 2H), 7.33 (m, 3H), 9.10 (s, 1H), 12.60 (s, 1H).
-
- To a solution of 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-hydroxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (100 mg, 0.22 mmol) in THF (5 mL) was added BH3/THF (1 M, 1.1 mL, 1.1 mmol) at 0° C. After addition, the reaction mixture was stirred for 16 hours at room temperature. The mixture was quenched with MeOH (10 mL), concentrated and the residue was purified on the prep-HPLC to give 1-(4-chlorobenzyl)-3-(3,3-dimethylbutyl)-2-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-5-ol (51 mg, 0.12 mmol, 55% yield). LCMS (ESI): m/z 428.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.85 (s, 6H), 1.06 (s, 9H), 1.48 (m, 2H), 2.63 (m, 4H), 3.16 (s, 2H), 4.78 (m, 1H), 5.36 (s, 1H), 6.48 (m, 1H), 6.78 (m, 3H), 7.00 (d, J=8.4 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 8.62 (s, 1H).
-
- Synthetic route for example 10
-
- To a solution of 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-hydroxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (2.2 g, 4.8 mmol) in DMF (50 mL) were added Cs2CO3 (4.7 g, 14.5 mmol) and iodomethane (2.1 g, 14.5 mmol). After addition, the reaction mixture was stirred for 2.0 hours at room temperature. The mixture was then concentrated and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give methyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoate (2.0 g, 4.1 mmol, 85% yield). 1HNMR (400 MHz, CDCl3): δ (ppm) 1.07 (s, 9H), 1.17 (s, 6H), 2.91 (s, 2H), 3.54 (s, 2H), 3.57 (s, 3H), 3.80 (s, 3H), 5.48 (s, 2H), 6.88-6.90 (m, 3H), 7.32-7.38 (m, 4H).
-
- To a solution of methyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoate (150 mg, 0.3 mmol) in THF (5 mL) and MeOH (5 mL) was added water (10 mL), followed by LiOH·H2O (130 mg, 3 mmol) at room temperature. After addition, the reaction mixture was stirred for 5 hours at 60° C. After cooled to room temperature, the mixture was acidified with 1.0 N HCl (aq) to pH=4.0 and extracted with DCM (2×10 mL). The organic extracts were combined and washed with brine (2×10 mL), dried over Na2SO4 and concentrated. The residue was purified on the pre-HPLC to give 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (70 mg, 0.15 mmol, 50% yield). LCMS (ESI): m/z 470.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.07 (s, 9H), 1.12 (s, 6H), 2.92 (s, 2H), 3.53 (s, 2H), 3.80 (s, 3H), 5.50 (s, 2H), 6.83 (d, J=7.2 Hz, 1H), 6.88 (d, J=8.4 Hz, 2H), 7.32-7.38 (m, 4H).
-
- To a solution of 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (120 mg, 0.26 mmol) in THF (10 mL) was added BH3/THF (1 M, 1.3 mL, 1.3 mmol) at 0° C. After addition, the reaction mixture was stirred for 16 hours at room temperature. The mixture was quenched with MeOH (10 mL), and concentrated. The residue was purified on the pre-HPLC to give 1-(4-chlorobenzyl)-3-(3,3-dimethylbutyl)-2-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-5-ol (30 mg, 0.07 mmol, 27% yield). LCMS (ESI): m/z 442.3 [M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.85 (s, 6H), 1.06 (s, 9H), 1.49 (m, 2H), 2.65 (m, 5H), 3.17 (s, 2H), 3.75 (s, 3H), 5.42 (s, 2H), 6.63-6.66 (m, 1H), 6.76 (d, J=8.4 Hz, 2H), 6.90 (s, 1H), 7.12 (d, J=9.2 Hz, 1H), 7.28 (d, J=8.4 Hz, 2H).
-
- Synthetic route for example 11
- To a solution of methyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoate (300 mg, 0.62 mmol) in THF (10 mL) was added LAH (47 mg, 1.24 mmol) at −78° C. After addition, the mixture was stirred for 1.0 hour at −78° C. The mixture was quenched with saturated Na2SO4 (aq, 1.0 mL). It was filtered and the filtrate was concentrated to give crude product which was then purified on the prep-HPLC (condition?) to give 1-(1-(4-chlorobenzyl)-2-(3-hydroxy-2,2-dimethylpropyl)-5-methoxy-1H-indol-3-yl)-3,3-dimethylbutan-1-one (98 mg, 0.22 mmol, 35% yield). LCMS (ESI): m/z 456.3 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.83 (s, 6H), 1.07 (s, 9H), 2.91 (s, 2H), 3.15 (m, 2H), 3.39 (s, 2H), 3.79 (s, 3H), 4.91 (t, 1H), 5.60 (s, 2H), 6.79-6.81 (m, 1H), 6.88 (d, J=8.4 Hz, 2H), 7.30-7.39 (m, 4H).
-
- Synthetic route for example 12
-
- The methyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoate (1.2 g, 2.5 mmol) and t-butylthiol (2.2 g, 25 mmol) were dissolved in CH2Cl2 (50 mL) and cooled to 0° C. AlCl3 (1.66 g, 12.5 mmol) was added in portions over 5 min. After addition, the mixture was stirred for 2.0 hours, and then poured into ice slowly. 1.0 N HCl (aq, 10 mL) was added and the mixture was extracted with CH2Cl2 (2×50 mL). The organic extracts were combined and washed with water (2×50 mL), dried over anhydrous MgSO4. It was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give methyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-hydroxy-1H-indol-2-yl)-2,2-dimethylpropanoate (780 mg, 1.7 mmol, 68% yield) as white solid. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.08 (s, 9H), 1.16 (s, 6H), 2.84 (s, 2H), 3.57 (s, 3H), 3.68 (s, 2H), 5.43 (s, 2H), 6.63-6.65 (m, 1H), 6.88 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.8 Hz, 1H), 7.29 (s, 1H), 7.34 (d, J=8.4 Hz, 2H), 9.11 (s, 1H).
-
- To a solution of methyl 3-(1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-hydroxy-1H-indol-2-yl)-2,2-dimethylpropanoate (200 mg, 0.43 mmol) in THF (10 mL) was added LAH (49 mg, 1.28 mmol) at −78° C. After addition, the mixture was stirred for 1.0 hour at −78° C. It was then quenched with saturated Na2SO4 (aq, 1.0 mL), filtered and the filtrate was concentrated to give crude product which was purified on the pre-HPLC to give 1-(1-(4-chlorobenzyl)-5-hydroxy-2-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-3-yl)-3,3-dimethylbutan-1-one (68 mg, 0.15 mmol, 35% yield). LCMS (ESI): m/z 441.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.83 (s, 6H), 1.08 (s, 9H), 2.84 (s, 2H), 3.14 (s, 2H), 3.33 (s, 2H), 4.88 (m, 1H), 5.56 (s, 2H), 6.60-6.63 (m, 1H), 6.88 (d, J=8.4 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H), 7.30-7.35 (m, 3H), 9.05 (s, 1H).
-
- Synthetic route for example 13
-
- To a mixture of 3-isopropylaniline B1′ (10 g, 74.1 mmol) in H2O (150 mL) were added conc.HCl (50 mL) and NaNO2 (7.7 g, 111.6 mmol) in portions in an ice-bath. The mixture was then stirred at 0-5° C. for 1.0 h. SnCl2 (28 g, 147.7 mmol) was added in portions and the mixture was stirred at room temperature for 2.0 h. The mixture was extracted with EtOAc (3×100 mL). The organic extracts were combined and dried over anhydrous Na2SO4, filtered and the filtrate was concentrated. The residue was dissolved in EtOAc (50 mL) and PE (50 mL). 6M HCl/1,4-dioxane (20 mL) was added. The mixture was stirred at room temperature for 2.0 h and filtered to give (3-isopropylphenyl)hydrazine hydrochloride 2 (11.3 g, 60.5 mmol, 82% yield) as white solid used as the intermediate without further purification.
-
- To a mixture of (3-isopropylphenyl)hydrazine hydrochloride B2′ (4 g, 21.4 mmol) and ethyl 5-(tert-butylthio)-2,2-dimethyl-4-oxopentanoate A4 (6 g, 23.0 mmol) in AcOH (30 mL) were added tolune (60 mL) and AcONa (2 g, 24.4 mmol). The mixture was stirred for 72 hours at room temperature. The mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=30:1) to give ethyl 5-(tert-butylthio)-2,2-dimethyl-4-oxopentanoate B3′ (1.9 g, 5.06 mmol, 24% yield) as yellow solid. LCMS (ESI): m/z 376.4[M+1]+.
-
- To a mixture of ethyl 3-(3-(tert-butylthio)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B3′ (500 mg, 1.33 mmol) in DMF (10 mL) were added NaH (100 mg, 2.50 mmol) and (bromomethyl)cyclobutane (250 mg, 1.68 mmol). The reaction mixture was stirred for 18 hours at room temperature. PE (60 mL) and EtOAc (10 mL) was added and the mixture was acidified by 2.0 N HCl (aq) to PH=4-5. The mixture was washed with water (2×40 mL), dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give 3-(3-(tert-butylthio)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid B4′ (380 mg, 0.91 mmol, 69% yield) as yellow oil used as the intermediate without further purification. LCMS (ESI): m/z 416.4[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.96 (s, 6H), 1.16 (s, 9H), 1.27 (d, J=6.8 Hz, 6H), 1.70-1.60 (m, 2H), 1.82-1.70 (m, 4H), 2.55 (s, 2H), 2.75-2.63 (m, 1H), 3.03-2.95 (m, 1H), 4.26 (d, J=7.2 Hz, 2H), 6.99 (d, J=8.4 Hz, 1H), 7.30 (s, 1H), 7.49 (d, J=8.0 Hz, 1H), 12.44 (brs, 1H).
-
- To a mixture of 3-(3-(tert-butylthio)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid B4′ (350 mg, 0.84 mmol) in DMF (5 mL) were added Cs2CO3 (400 mg, 1.23 mmol) and Mel (200 mg, 1.41 mmol). The mixture was stirred for 18 hours at room temperature. To the mixture were added PE (50 mL) and EtOAc (10 mL). The mixture was washed with water (2×40 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated to give methyl 3-(3-(tert-butylthio)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B5′ (360 mg, 0.84 mmol, 99% yield) as yellow oil. LCMS (ESI): m/z 430.5[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.16 (s, 6H), 1.22 (s, 9H), 1.32 (d, J=6.8 Hz, 6H), 1.72-1.67 (m, 2H), 1.90-1.79 (m, 4H), 2.80-2.70 (m, 1H), 3.08-2.98 (m, 1H), 3.37 (s, 2H), 3.70 (s, 3H), 4.15 (d, J=7.2 Hz, 2H), 7.03 (d, J=8.0 Hz, 1H), 7.10 (s, 1H), 7.64 (d, J=8.4 Hz, 1H).
-
- To a mixture of methyl 3-(3-(tert-butylthio)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B5′ (360 mg, 0.84 mmol) in DCM (20 mL) was added AlCl3 (800 mg, 5.99 mmol). The mixture was stirred for 18 hat room temperature. The mixture was quenched with water (20 mL). The organic layer was separated and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated to give methyl 3-(1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B6′ (190 mg, 0.56 mmol, 66% yield) as brown oil used as the intermediate without further purification.
-
- To a mixture of methyl 3-(1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate B6′ (100 mg, 0.29 mmol) in DCE (10 mL) were added AlCl3 (150 mg, 1.12 mmol) and 4-chlorobenzoyl chloride (150 mg, 0.86 mmol). The mixture was heated to reflux for 18 h. The mixture was quenched with water (10 mL). The organic layer was separated and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by preparation TLC (PE:EA=5:1) to give methyl 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate (28) (72 mg, 0.15 mmol, 51% yield) as yellow oil. LCMS (ESI): m/z 480.2[M+Na]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.18 (s, 6H), 1.29 (d, J=6.8 Hz, 6H), 1.88-1.77 (m, 4H), 2.01-1.99 (m, 2H), 2.80-2.65 (m, 1H), 3.05-2.95 (m, 1H), 3.61 (s, 5H), 4.21 (d, J=6.8 Hz, 2H), 6.91 (s, 2H), 7.15 (s, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H).
-
- To a mixture of methyl 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate 40 (50 mg, 0.104 mmol) in THF (5 mL) were added lithium hydroxide monohydrate (30 mg, 0.714 mmol) and water (1.0 mL). The mixture was heated to 60° C. for 18 h. After cooling to room temperature, the mixture was concentrated and the residue was purified by pre-HPLC to give 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid (39) (24 mg, 0.052 mmol, 49% yield) as white solid. LCMS (ESI): m/z 466.3[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.03 (s, 6H), 1.25 (d, J=6.8 Hz, 6H), 1.91-1.73 (m, 6H), 2.75-2.70 (m, 1H), 2.99-2.95 (m, 1H), 3.44 (s, 2H), 4.34 (d, J=6.4 Hz, 2H), 6.81 (d, J=8.4 Hz, 1H), 6.93 (d, J=8.0 Hz, 1H), 7.43 (s, 1H), 7.70-7.58 (m, 4H), 12.43 (brs, 1H).
-
- The compound 29 was prepared by the method similar to the compound 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid, but using (3-methoxyphenyl)hydrazine hydrochloride (step 13.2). LCMS (ESI): m/z 440.3[M+1]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.00 (s, 6H), 1.91-1.74 (m, 6H), 2.70-2.65 (m, 1H), 3.39 (s, 2H), 4.21 (d, J=7.2 Hz, 2H), 6.55 (d, J=2.0 Hz, 1H), 6.72 (d, J=8.8 Hz, 1H), 6.86 (d, J=1.6 Hz, 1H), 7.65-7.57 (m, 4H), 9.24 (s, 1H), 12.39 (brs, 1H).
-
- The compound 30 was prepared by the method similar to the compound methyl 3-(3-(4-chlorobenzoyl)-1-(cyclobutylmethyl)-6-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoate, but using (3-methoxyphenyl)hydrazine hydrochloride (step 13.2). LCMS (ESI): m/z 468.2[M+1]+. 1H NMR (400 MHz, CDCl3+CD3OD): δ ppm 1.23 (t, J=6.8 Hz, 3H), 1.29 (s, 6H), 1.85-1.74 (m, 4H), 1.98-1.94 (m, 2H), 2.76-2.73 (m, 1H), 3.06 (s, 2H), 3.38 (s, 2H), 4.18-4.11 (m, 2H), 6.23 (s, 1H), 6.89-6.87 (m, 1H), 7.15 (s, 1H), 7.52-7.49 (m, 3H), 8.19-8.16 (m, 2H).
-
- Synthetic route for example 15
-
- The compound H4 was prepared by the method similar to the compound B3 in example 1, but using different aniline as the starting material. LCMS (ESI): m/z 488.3[M+1]+.
-
- The compound H5 was prepared by the similar method to the prepararat on of compound 1 in the step 1.8. LCMS (ESI): m/z 460.2[M+1]+.
-
- To a mixture of 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (6 g, 13.0 mmol) in THF (100 mL) was added NH4Cl (1.05 g, 19.6 mmol), HATU (7.5 g, 19.7 mmol) and TEA (3 g, 29.7 mmol). The mixture was stirred at room temperature for 18 hours. The mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=2:1) to give 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanamide H6 (5.6 g, 12.2 mmol, 93% yield) as yellow solid. LCMS (ESI): m/z 459.2[M+H]+.
-
- To a mixture of 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanamide (200 mg, 0.44 mmol) in toluene (10 mL) was added 1-chloropropan-2-one (300 mg, 3.24 mmol). The mixture was heated to 110° C. for 18 hours. After cooling to room temperature, the mixture was concentrated and the residue was purified by prep-HPLC to give 2-(1-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2-methylpropan-2-yl)-4-methyloxazole (38 mg, 0.076 mmol, 17% yield) as white solid. LCMS (ESI): m/z 497.3[M+H]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.26 (s, 9H), 1.42 (s, 6H), 2.17 (s, 3H), 3.32 (s, 2H), 3.86 (s, 3H), 4.89 (s, 2H), 6.63 (d, J=8.4 Hz, 2H), 6.77-6.74 (m, 1H), 6.94 (d, J=8.8 Hz, 1H), 7.16 (d, J=8.4 Hz, 2H), 7.26-7.24 (m, 2H).
-
- To a mixture of 2-(1-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2-methylpropan-2-yl)-4-methyloxazole (60 mg, 0.12 mmol) in DCM (10 mL) were added t-BuSH (300 mg, 3.33 mmol) and AlCl3 (200 mg, 1.50 mmol). The mixture was stirred for 18 hours at room temperature. The mixture was diluted with water (10 mL) and extracted with dichloromethane. The organic extract was dried over anhydrous Na2SO4, filtered and the filtrate was concentrated. The residue was purified by preparation HPLC to give 3-(tert-butylthio)-1-(4-chlorobenzyl)-2-(2-methyl-2-(4-methyloxazol-2-yl)propyl)-1H-indol-5-ol (32 mg, 0.066 mmol, 55% yield) as white solid. LCMS (ESI): m/z 483.2[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.18 (s, 9H), 1.28 (s, 6H), 2.05 (s, 3H), 3.23 (s, 2H), 4.95 (s, 2H), 6.58-6.55 (m, 1H), 6.77-6.74 (m, 2H), 6.97 (d, J=2.4 Hz, 1H), 7.10 (d, J=8.8 Hz, 1H), 7.30 (d, J=8.4 Hz, 2H), 7.68 (d, J=1.2 Hz, 1H), 8.84 (brs, 1H).
-
- Synthetic route for example 16
-
- To a mixture of 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanoic acid (500 mg, 1.09 mmol) in DCM (10 mL) was added N-hydroxypropionimidamide (150 mg, 1.70 mmol), HATU (700 mg, 1.84 mmol) and TEA (500 mg, 4.95 mmol). The mixture was stirred for 18 hours at room temperature. The mixture was concentrated and the residue was purified by preparation HPLC to give 5-(1-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2-methylpropan-2-yl)-3-ethyl-1,2,4-oxadiazole (62 mg, 0.12 mmol, 11% yield) as white solid. LCMS (ESI): m/z 512.2[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.17 (s, 9H), 1.21 (t, J=7.2 Hz, 3H), 1.41 (s, 6H), 2.70-2.63 (q, J=7.6 Hz, 2H), 3.36 (s, 2H), 3.75 (s, 3H), 5.27 (s, 2H), 6.75-6.72 (m, 1H), 6.82 (d, J=8.8 Hz, 2H), 7.06 (d, J=2.4 Hz, 1H), 7.24 (d, J=8.8 Hz, 1H), 7.32 (d, J=8.4 Hz, 2H).
-
- To a mixture of 5-(1-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2-methylpropan-2-yl)-3-ethyl-1,2,4-oxadiazole (50 mg, 0.10 mmol) in DCM (10 mL) was added t-BuSH (300 mg, 3.33 mmol) and AlCl3 (200 mg, 1.50 mmol). The mixture was stirred for 18 hours at room temperature. The mixture was diluted with water (10 mL) and extracted with DCM. The organic extract was dried over anhydrous Na2SO4, filtered and the filtrate was concentrated. The residue was purified by prep-HPLC to give 3-(tert-butylthio)-1-(4-chlorobenzyl)-2-(2-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methylpropyl)-1H-indol-5-ol (15 mg, 0.030 mmol, 30% yield) as white solid. LCMS (ESI): m/z 498.2[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.16 (s, 9H), 1.21 (t, J=7.6 Hz, 6H), 1.42 (s, 6H), 2.70-2.63 (q, 2H), 3.34 (s, 2H), 5.22 (s, 2H), 6.60-6.56 (m, 1H), 6.81 (d, J=8.4 Hz, 2H), 6.95 (d, J=2.0 Hz, 1H), 7.12 (d, J=8.8 Hz, 1H), 7.33-7.30 (m, 2H), 8.89 (brs, 1H).
-
- Synthetic route for example 17
-
- To a mixture of 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanamide (1.0 g, 2.18 mmol) in DCM (50 mL) was added pyridine (5 mL) and TFAA (1.5 g, 7.14 mmol) dropwise in an ice-bath. The mixture was stirred for 1.0 hour at room temperature and then washed with 1.0 N HCl (3×50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and the filtrate was concentrated to give 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanenitrile (620 mg, 1.41 mmol, 64% yield) as yellow solid. LCMS (ESI): m/z 441.2[M+H]+.
-
- To a mixture of 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-1H-indol-2-yl)-2,2-dimethylpropanenitrile (500 mg, 1.13 mmol) and 2-(dimethylamino)ethanol (100 mg, 1.12 mmol) in diglyme (10 mL) was added HCl/1,4-dioxane (1 mL, 4 mmol, 4.0 M). The mixture was stirred for 15 min at room temperature. 2-(dimethylamino)ethanol (300 mg, 3.37 mmol) and NaN3 (180 mg, 2.77 mmol) were added. The mixture was heated to 130° C. for 72 hours. After cooling to room temperature, the mixture was concentrated. The residue was diluted with water (50 mL) and extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and the filtrate was concentrated to give 3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-2-(2-methyl-2-(1H-tetrazol-5-yl)propyl)-1H-indole (420 mg, 0.87 mmol, 77% yield) as yellow oil used in the next step without further purification. LCMS (ESI): m/z 484.3[M+H]+.
-
- To a mixture of 3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-2-(2-methyl-2-(1H-tetrazol-5-yl)propyl)-1H-indole H8 (500 mg, 1.03 mmol) in DMF (10 mL) was added Cs2CO3 (1 g, 3.08 mmol) and Mel (1.2 g, 8.51 mmol). The reaction mixture was heated to 50° C. for 18 hours. After cooling to room temperature, the mixture was diluted with PE (50 mL) and EtOAc (50 mL). The resulting solution was washed with water (3×50 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated to give crude product (700 mg). The crude product (200 mg) was purified by pre-HPLC to give 3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-2-(2-methyl-2-(1-methyl-1H-tetrazol-5-yl)propyl)-1H-indole 35 (10 mg, 0.020 mmol, 7% yield) and 3-(tert-butylthio)-1-(4-chlorobenzyl)-5-methoxy-2-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)-1H-indole 36 (22 mg, 0.044 mmol, 15% yield) as white solid. LCMS (ESI) (compound 35): m/z 498.3[M+H]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.27 (s, 9H), 1.66 (s, 6H), 3.33-3.20 (m, 5H), 3.87 (s, 3H), 4.52 (s, 2H), 6.54 (d, J=8.4 Hz, 2H), 6.83-6.79 (m, 1H), 6.98 (d, J=8.8 Hz, 1H), 7.14 (d, J=8.4 Hz, 2H), 7.26-7.24 (m, 1H). LCMS (ESI) (compound 36): m/z 498.3[M+H]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.25 (s, 9H), 1.47 (s, 6H), 3.42 (s, 2H), 3.86 (s, 3H), 4.20 (s, 3H), 5.08 (s, 2H), 6.54 (d, J=8.4 Hz, 2H), 6.76-6.73 (m, 1H), 6.91 (d, J=8.8 Hz, 1H), 7.16 (d, J=8.4 Hz, 2H), 7.26-7.24 (m, 1H).
-
- To a mixture of two isomers 35 and 36 (500 mg, 0.74 mmol) in DCM (30 mL) was added t-BuSH (3 g, 33.3 mmol) and AlCl3 (1.8 g, 13.5 mmol). The reaction mixture was stirred for 18 hours at room temperature. The mixture was washed with water (20 mL), dried over anhydrous Na2SO4, filtered, the filtrate was concentrated. The residue was purified by preparation HPLC to give 3-(tert-butylthio)-1-(4-chlorobenzyl)-2-(2-methyl-2-(1-methyl-1H-tetrazol-5-yl)propyl)-1H-indol-5-ol (62 mg, 0.13 mmol, 17% yield) and 3-(tert-butylthio)-1-(4-chlorobenzyl)-2-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)-1H-indol-5-ol (120 mg, 0.25 mmol, 34% yield) as white solid. LCMS (ESI) (compound 37): m/z 484.3[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.14 (s, 9H), 1.50 (s, 6H), 4.05-3.75 (m, 5H), 5.26 (s, 2H), 6.60-6.57 (m, 1H), 6.82 (d, J=8.4 Hz, 2H), 6.90 (d, J=2.0 Hz, 1H), 7.15 (d, J=8.0 Hz, 1H), 7.31 (d, J=8.4 Hz, 2H), 8.88 (brs, 1H). LCMS (ESI) (compound 38): m/z 484.3[M+H]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.16 (s, 7H), 1.20 (s, 2H), 1.40 (s, 6H), 3.27-3.30 (s, 2H), 4.29 (s, 3H), 5.07 (s, 1.49H), 5.58 (s, 0.45H), 6.55-6.63 (m1H), 6.77 (d, J=8.4 Hz, 1.53H), 6.88 (d, J=8.4 Hz, 0.49H), 6.95-7.01 (m, 1H), 7.07 (d, J=8.8 Hz, 0.8H), 7.18 (d, J=8.8 Hz, 0.26H), 7.28-7.34 (m, 2H), 8.86 (brs, 1H).
-
- Synthetic route for example 18
-
- To a solution of methyl 2-(4-bromophenyl)acetate (2.29 g, 10 mmol) in THF (100 mL) was added LDA (2.0 M, 6 mL, 12 mmol) at −70° C. under N2. After addition, the reaction mixture was stirred for 30 min at 0° C. The mixture was then cooled to −70° C. again and iodomethane (1.7 g, 12 mmol) was added. After addition, the reaction mixture was stirred for 1.0 hour at 0° C. The mixture was quenched with water (50 mL) and extracted with EtOAc (3×50 mL). The organic extracts were washed with brine (2×50 mL), dried over anhydrous Na2SO4 and concentrated to give methyl 2-(4-bromophenyl) propanoate (2.3 g, 9.5 mmol, 95% yield) as yellow oil used as the intermediate without further purification. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.48 (d, J=7.2 Hz, 3H), 3.65-3.71 (m, 4H), 7.17 (d, J=8.4 Hz, 2H), 7.48 (d, J=8.4 Hz, 2H).
-
- To a mixture of methyl 2-(4-bromophenyl)propanoate (2.3 g, 9.5 mmol) in THF (20 mL) and MeOH (20 mL) were added LiOH·H2O (4.0 g, 95 mmol) and water (40 mL). The mixture was heated to 65° C. for 3 hours. After cooling to room temperature, the mixture was concentrated. The residue was diluted with water and acidified with 1.0 N HCl (aq) to pH=4. The resulting mixture was extracted with DCM (2×50 mL) and the organic extracts were washed with brine (2×50 mL), dried over anhydrous Na2SO4 and concentrated to give crude 2-(4-bromophenyl)propanoic acid (2.2 g, 9.5 mmol, 100% yield) as yellow oil used as the intermediate without further purification. LCMS (ESI): m/z 229[M+1]+.
-
- To a solution of N1-(2-chlorobenzyl)-4-methoxybenzene-1,2-diamine (2.62 g, 10 mmol) in DCM (50 mL) were added 2-(4-bromophenyl)propanoic acid (2.2 g, 9.6 mmol), TEA (5.05 g, 50 mmol) and HATU (5.7 g, 15 mmol) at room temperature. After addition, the reaction mixture was stirred for 24 hours at room temperature. Then it was concentrated, and the residue was purified by column chromatography on silica gel (PE:EA=1:2) to give 2-(4-bromophenyl)-N-(2-((2-chlorobenzyl)amino)-5-methoxyphenyl)propanamide (4.1 g, 8.7 mmol, 91% yield) as brown solid. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.42 (d, J=6.8 Hz, 3H), 3.62 (s, 3H), 3.88-3.93 (m, 1H), 4.29 (d, J=6.0 Hz, 2H), 4.93-4.96 (m, 1H), 6.43 (d, J=8.8 Hz, 1H), 6.61 (d, J=8.8 Hz, 1H), 6.85 (d, J=2.8 Hz, 1H), 7.27-7.37 (m, 5H), 7.44-7.51 (m, 3H), 9.48 (s, 1H).
-
- The mixture of 2-(4-bromophenyl)-N-(2-((2-chlorobenzyl)amino)-5-methoxyphenyl) propanamide (20 g, 4.2 mmol) in AcOH (40 mL) was stirred for 16 hat 120° C. After cooling to room temperature, the mixture was concentrated, and the residue was purified by column chromatography on silicagel (PE:EA=5:1) to give 2-(1-(4-bromophenyl)ethyl)-1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazole (1.5 g, 3.3 mmol, 79% yield). LCMS (ESI): m/z 455.1[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.94 (d, J=7.2 Hz, 3H), 3.91 (s, 3H), 4.40-4.46 (m, 1H), 5.36 (s, 2H), 6.14 (d, J=7.6 Hz, 1H), 6.97-7.04 (m, 2H), 7.03-7.13 (m, 3H), 7.24-7.27 (m, 1H), 7.32 (d, J=8.8 Hz, 2H), 7.41 (d, J=8.4 Hz, 1H), 7.60 (d, J=2.4 Hz, 1H).
-
- To a solution of 2-(1-(4-bromophenyl)ethyl)-1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazole (1.9 g, 4.2 mmol) in DMF (50 mL) were added Pd(PPh3)4 (473 mg, 0.42 mmol) and Zn(CN)2 (490 mg, 4.2 mmol) at room temperature under N2. After addition, the reaction mixture was stirred for 16 hours at 80° C. The mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=3:1) to give 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)benzonitrile (1.5 g, 3.7 mmol, 88% yield). LCMS (ESI): m/z 402.2[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.87 (d, J=7.2 Hz, 3H), 3.90 (s, 3H), 4.33-4.34 (m, 1H), 5.20-5.35 (m, 2H), 6.11 (d, J=7.6 Hz, 1H), 6.90-6.96 (m, 2H), 7.07 (d, J=9.2 Hz, 1H), 7.17-7.2 (m, 1H), 7.31 (d, J=8.4 Hz, 2H), 7.37 (d, J=7.2 Hz, 1H), 7.42-7.47 (m, 3H).
-
- To a solution of 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)benzonitrile (1.5 g, 3.74 mmol) in MeOH (20 mL) were added water (50 mL) and KOH (4.19 g, 7.48 mmol). The mixture was heated to 115° C. for 24 hours. After cooling to room temperature, the organic solvente was evaporated and the residue was acidified with 1.0N HCl (aq) to pH=4. The resulting mixture was extracted with DCM (2×50 mL), and the organic extracts were washed with brine (2×50 mL), dried over Na2SO4 and concentrated to give 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)benzoic acid (1.4 g, 3.3 mmol, 88% yield). LCMS (ESI): m/z 421.3[M+1]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.74 (d, J=7.2 Hz, 3H), 3.84 (s, 3H), 4.77-4.79 (m, 1H), 5.55-5.66 (m, 2H), 6.24 (d, J=7.6 Hz, 1H), 6.97-7.01 (m, 2H), 7.18-7.22 (m, 1H), 7.30-7.37 (m, 4H), 7.43 (d, J=7.6 Hz, 1H), 7.73 (d, J=8.4 Hz, 2H), 13.20 (s, 1H).
-
- To a solution of 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl) ethyl)benzoic acid (1.2 g, 2.9 mmol) in DMF (50 mL) were added Cs2CO3 (2.9 g, 8.6 mmol) and iodomethane (618 mg, 4.35 mmol). After addition, the reaction mixture was stirred for 2 hours at room temperature. It was then concentrated and the residue was purified by column chromatography on silica gel (PE:EA=5:1) to give methyl 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)benzoate (1.2 g, 2.8 mmol, 96% yield). LCMS (ESI): m/z 435.2[M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.88 (d, J=7.2 Hz, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 4.30-4.36 (m, 1H), 5.20-5.31 (m, 2H), 6.18 (d, J=7.6 Hz, 1H), 6.91-6.95 (m, 2H), 7.04 (d, J=8.8 Hz, 1H), 7.14-7.18 (m, 1H), 7.27 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 1H), 7.50 (s, 1H), 7.85 (d, J=8.4 Hz, 2H).
-
- To a solution of methyl 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazole-2-yl)ethyl)benzoate (1.1 g, 2.5 mmol) in THF (50 mL) was added LAH (193 mg, 5 mmol) at 0° C. After addition, the reaction mixture was stirred for 2 h at room temperature. It was then quenched with 1.0 N NaOH (1.0 mL), filtered and concentrated to give (4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)phenyl)methanol (0.9 g, 2.2 mmol, 88% yield). LCMS (ESI): m/z 407.3[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 7.61 (s, 1H), 7.42 (d, J=8.0 Hz, 1H), 7.22-7.24 (m, 5H), 7.08 (d, J=8.8 Hz, 1H), 7.00-7.04 (m, 3H), 6.21 (d, J=7.6 Hz, 1H), 5.36 (s, 2H), 4.60 (s, 2H), 4.46-4.48 (m, 1H), 3.89 (s, 3H), 1.95 (d, J=7.2 Hz, 3H).
-
- To a solution of (4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl) ethyl)phenyl)methanol (0.8 g, 2.0 mmol) in DCM (20 mL) were added TEA (1.0 g, 10 mmol) and MsCl (344 mg, 3.0 mmol) at 0° C. After addition, the reaction mixture was stirred for 2 h at 0° C. The mixture was then concentrated to give the intermediate 4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)benzyl methanesulfonate. The above intermediate was dissolved in DMF (20 mL) and NaCN (196 mg, 4.0 mmol) was added at room temperature. The reaction mixture was stirred for 16 h at room temperature, and then it was concentrated. The crude product was purified by column chromatography on silica gel (PE:EA=5:1) to give 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl) ethyl)phenyl) acetonitrile (260 mg, 0.7 mmol, 35% yield). LCMS (ESI): m/z 415.3[M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.96 (d, J=7.2 Hz, 3H), 3.64 (s, 2H), 3.91 (s, 3H), 4.49-4.54 (m, 1H), 5.40 (m, 2H), 6.18 (d, J=7.6 Hz, 1H), 7.00-7.08 (m, 2H), 7.14-7.20 (m, 3H), 7.25-7.28 (m, 3H), 7.43 d, J=8.0 Hz, 1H), 7.53 (s, 1H).
-
- To a solution of 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)phenyl) acetonitrile (250 mg, 0.6 mmol) in MeOH (10 mL) were added water (20 mL) and KOH (337 mg, 6 mmol). The reaction mixture was heated to 115° C. for 24 h. After cooling to room temperature, the organic solvente was evaporated and the aqoues layer was acidified with 1.0 N HCl (aq) to pH=4.0. The resulting mixture was extracted with DCM (2×50 mL). The organic extracts were washed with brine (2×50 mL), dried over anhydrous Na2SO4 and concentrated to give 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)phenyl)acetic acid (20 mg, 0.05 mmol, 9% yield). LCMS (ESI): m/z 435.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.68 (d, J=6.8 Hz, 3H), 3.44 (s, 2H), 3.81 (s, 3H), 4.93-4.51 (m, 1H), 5.40-5.82 (m, 2H), 6.19 (d, J=8.0 Hz, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.09-7.04 (m, 1H), 7.08 (d, J=8.0 Hz, 2H), 7.14 (d, J=7.2 Hz, 2H), 7.25-7.27 (m, 2H), 7.17-7.28 (m, 3H), 7.46 (d, J=7.6 Hz, 1H), 12.50 (s, 1H).
-
- To a solution of 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)phenyl)acetic acid (380 mg, 0.87 mmol) in DMF (5 mL) were added K2CO3 (120 mg g, 0.87 mmol) and iodomethane (127 mg, 0.87 mmol). After addition, the reaction mixture was stirred for 2 h at room temperature. The mixture was diluted with water and extracted with ethyl acetate. The organic extract was washed with water and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=5:1) to give methyl 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)phenyl) acetate (310 mg, 0.69 mmol, 79% yield) as white solid. LCMS (ESI): m/z 449.2[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.72 (d, J=7.2 Hz, 2H), 3.56 (s, 2H), 3.59 (s, 3H), 3.83 (s, 3H), 4.64 (m, 1H), 5.46-5.65 (m, 2H), 6.27 (d, J=7.6 Hz, 1H), 6.94 (m, 1H), 7.03 (m, 1H), 7.08 (d, J=8.4 Hz, 2H). 7.19 (d, J=8.4 Hz, 2H), 7.22 (m, 1H), 7.29-7.33 (m, 2H), 7.45 (d, J=8.0 Hz, 2H).
-
- To a solution of methyl 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo [d]imidazol-2-yl)ethyl)phenyl)acetate (100 mg, 0.22 mmol) in THF (5 mL) was added LAH (9 mg, 0.22 mmol) at 0° C. After addition, the reaction mixture was stirred for 2 h at room temperature. The mixture was quenche with 1.0 N NaOH (1.0 mL), filtrated and concentrated. The residue was purified by pre-HPLC to give 2-(4-(1-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)ethyl)phenyl)ethanol (10 mg, 0.023 mmol, 10.8% yield) as white solid. LCMS (ESI): m/z 421.2 [M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 1.72 (d, J=6.8 Hz, 3H), 2.62 (t, d, J=7.2 Hz, 2H), 3.48 (d, J=7.2 Hz, 2H), 3.83 (s, 3H), 4.64 (m, 1H), 5.61 (m, 2H), 6.24 (d, J=7.6 Hz, 1H), 7.05-6.96 (m, 4H), 7.14-7.10 (d, J=8.0 Hz, 2H), 7.22-7.28 (m, 2H), 7.34 (d, J=8.8 Hz, 1H), 7.47 (d, J=8.0 Hz, 1H).
-
- Synthetic route for example 19
-
- To a solution of 2-(4-isobutylphenyl)propanoic acid (20.6 g, 100 mmol) in THF (200 mL) were added N,O-dimethylhydroxylamine hydrochloride (9.6 g, 100 mmol), TEA (30.3 g, 300 mmol), and HATU (45.6 g, 120 mmol) at room temperature. After addition, the reaction mixture was stirred for 16 h at room temperature. It was then concentrated, and the residue was purified by column chromatography on silica gel (PE:EA=20:1) to give 2-(4-isobutylphenyl)-N-methoxy-N-methylpropanamide (24.0 g, 96 mmol, 96% yield) as colorless oil. LCMS (ESI): m/z 250.1[M+1]+.
-
- To a solution of 2-(4-isobutylphenyl)-N-methoxy-N-methylpropanamide (20.6 g, 83 mmol) in THF (200 mL) was added LAH (3.14 g, 83 mmol) at 0° C. After addition, the reaction mixture was stirred for 1.0 h at room temperature. The mixture was quenched with saturated Na2SO4 (aq, 6 mL), filtered and concentrated to give 2-(4-isobutylphenyl)propanal (14.8 g, 78 mmol, 94% yield) as colorless oil used as the intermediate without further purification. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.90 (d, J=8.0 Hz, 6H), 1.42 (d, J=6.8 Hz, 3H), 1.82-1.89 (m, 1H), 2.46 (d, J=7.2 Hz, 2H), 3.57-3.61 (m, 1H), 7.10-7.17 (m, 4H), 9.67 (s, 1H).
-
- To a solution of CBr4 (5.05 g, 15.2 mmol) in DCM (30 mL) was added the solution of PPh3 (3.98 g, 15.2 mmol) in DCM (20 mL) at 0° C. After addition, the reaction mixture was stirred for 30 min at 0° C. The solution of 2-(4-isobutylphenyl)propanal (2.4 g, 12.6 mmol) in DCM (20 mL) was then added at 0° C. After addition, the reaction mixture was stirred at 0° C. for 2 h, and then quenched with water (50 mL). The organic layer was separated and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=30:1) to give 1-(4,4-dibromobut-3-en-2-yl)-4-isobutylbenzene (3.1 g, 9 mmol, 71% yield) as colorless oil. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.90 (d, J=6.4 Hz, 6H), 1.38 (d, J=6.8 Hz, 3H), 1.82-1.88 (m, 1H), 2.44 (d, J=7.2 Hz, 2H), 3.71-3.75 (m, 1H), 6.49 (d, J=9.6 Hz, 1H), 7.08-7.26 (m, 4H).
-
- To a solution of 1-(4,4-dibromobut-3-en-2-yl)-4-isobutylbenzene (3.1 g, 9 mmol) in THF (80 mL) was added n-BuLi (22.5 mL, 36 mmol) at −70° C. After addition, the reaction mixture was stirred at −70° C. for 2 h. Then it was quenched with NH4Cl (aq, 60 mL), extracted with EOAc (2×50 mL). The organic extracts were concentrated to give 1-(but-3-yn-2-yl)-4-isobutylbenzene (2.0 g, 9 mmol, 100% yield) as yellow oil. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.90 (d, J=6.8 Hz, 6H), 1.49 (d, J=7.2 Hz, 3H), 1.81-1.88 (m, 1H), 2.25 (d, J=2.4 Hz, 1H), 2.45 (d, J=7.2 Hz, 2H), 3.71-3.77 (m, 1H), 7.10 (d, J=8.0 Hz, 1H), 7.28 (d, J=8.0 Hz, 1H).
-
- To a solution of 4-methoxyaniline (12.3 g, 100 mmol) in AcOH (100 mL) was added bromine (16 g, 100 mmol) at 0° C. After addition, the reaction mixture was stirred at 0° C. for 2 h. Then it was quenched with water (100 mL), extracted with EtOAc (2×50 mL). The organic extracts were combined and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give 2-bromo-4-methoxyaniline (7.8 g, 39 mmol, 39% yield). 1H NMR (400 MHz, DMSO-d6): δ (ppm) 3.65 (s, 3H), 4.82 (s, 2H), 6.74-6.78 (m, 2H), 6.97 (d, J=2.4 Hz, 1H).
-
- To a solution of 2-bromo-4-methoxyaniline (3.0 g, 14.9 mmol) in DMF (80 mL) were added 1-chloro-3-(chloromethyl)benzene (2.4 g, 14.9 mmol) and K2CO3 (6.15 g, 44.6 mmol) at room temperature. After addition, the reaction mixture was stirred at 80° C. for 12 h. Then it was quenched with water (100 mL), extracted with EtOAc (2×50 mL). The organic extracts were combined and concentrated. The residue was purified by column chromatography on silicagel (PE:EA=20:1) to give 2-bromo-N-(3-chlorobenzyl)-4-methoxyaniline (2.0 g, 6 mmol, 42% yield) as yellow oil. LCMS (ESI): m/z 328.1 [M+1]+.
-
- To a solution of 2-bromo-N-(3-chlorobenzyl)-4-methoxyaniline (2.0 g, 6 mmol) in THF (50 mL) was added 1-(but-3-yn-2-yl)-4-isobutylbenzene (1.14 g, 6 mmol), Pd(PPh3)2Cl2 (500 mg), CuI (50 mg) and TEA (1.8 g, 18 mmol) at room temperature under N2, after addition, the reaction mixture was stirred at 80° C. for 24 h. After cooling to room temperature, the mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give N-(3-chlorobenzyl)-2-(3-(4-isobutylphenyl)but-1-yn-1-yl)-4-methoxyaniline (1.0 g, 2.3 mmol, 38% yield) as yellow oil.
-
- To a solution of crude N-(3-chlorobenzyl)-2-(3-(4-isobutylphenyl)but-1-yn-1-yl)-4-methoxyaniline (1.0 g, 2.3 mmol) in DME (40 mL) was added potassium 2-methylpropan-2-olate (515 mg, 4.6 mmol) at room temperature. After addition, the reaction mixture was stirred for 14 h at 50° C. It was then concentrated and the residue was purified by column chromatography on silica gel (PE:EA=20:1) to give 1-(3-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-5-methoxy-1H-indole (300 mg, 0.7 mmol, 30% yield) as white solid. LCMS (ESI): m/z 432.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.80-0.82 (m, 6H), 1.58 (d, J=7.2 Hz, 3H), 1.71-1.78 (m, 1H), 2.34 (d, J=7.6 Hz, 2H), 3.75 (s, 3H), 4.17-4.22 (m, 1H), 5.04-5.38 (m, 2H), 6.50 (s, 1H), 6.65-6.72 (m, 3H), 6.97-6.99 (m, 2H), 7.05-7.08 (m, 3H), 7.17-7.21 (m, 2H).
-
- The 1-(3-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-5-methoxy-1H-indole (300 mg, 0.7 mmol) and t-butylthiol (0.48 g, 5.3 mmol) were dissolved in CH2Cl2 (20 mL) and cooled to 0° C. AlCl3 (0.36 mg, 2.7 mmol) was added in portions over 5 min. The mixture stirred for 2 h, and then poured into ice slowly. 1.0 N HCl (10 mL) was added and the mixture extracted with CH2Cl2 (2×20 mL). The organic extracts were washed with water (2×20 mL), dried (MgSO4), and concentrated. The crude product was purified by column chromatography on silica gel (PE:EA=10:1) to give 1-(3-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-indol-5-ol (180 mg, 0.42 mmol, 60% yield) as white solid. LCMS (ESI): m/z 418.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.80-0.83 (m, 6H), 1.52-1.57 (m, 3H), 1.71-1.78 (m, 1H), 2.34 (d, J=6.8 Hz, 2H), 4.14-4.19 (m, 1H), 5.00-5.33 (m, 2H), 6.40 (s, 1H), 6.51-6.53 (m, 1H), 6.65 (s, 1H), 6.71-6.73 (m, 1H), 6.88 (d, J=2.0 Hz, 1H), 6.93-6.99 (m, 3H), 7.07 (d, J=8.0 Hz, 2H), 7.12-7.21 (m, 2H), 8.66 (s, 1H).
-
- Synthetic route for example 20
-
- To a solution of 4-methoxy-2-nitroaniline (5.04 g, 30 mmol) and 1-chloro-2-(chloromethyl)benzene (4.83 g, 30 mmol) in DMF (100 mL) was added DIPEA (1.65 mL, 90 mmol) at room temperature under N2. After addition, the reaction mixture was stirred for 48 h at 140° C. After cooling to room temperature, the mixture was quenched with water (100 mL), extracted with EtOAc (3×100 mL). The organic extracts were combined and washed with brine (3×100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give N-(2-chlorobenzyl)-4-methoxy-2-nitroaniline (4.0 g, 14 mmol, 46% yield) as red solid. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 3.74 (s, 3H), 4.67 (d, J=6.0 Hz, 2H), 6.79 (d, J=9.6 Hz 1H), 7.23 (dd, J=9.2, 2.8 Hz, 1H), 7.28-7.32 (m, 3H), 7.47-7.51 (m, 1H), 7.55 (d, J=2.8 Hz, 1H), 8.54 (t, J=6.0 Hz, 1H).
-
- To a solution of N-(2-chlorobenzyl)-4-methoxy-2-nitroaniline (1.45 g, 5 mmol) in EtOH (50 mL) were added Fe (2.78 g, 50 mmol), NH4Cl (5.3 g, 100 mmol) and water (10 mL) at room temperature. After addition, the reaction mixture was stirred for 4 hours at 80° C. After cooling to room temperature, the reaction mixture was extracted with ethyl acetate (3×100 mL). The organic extracts were combined and washed with brine (3×100 mL), dried over anhydrous Na2SO4 and concentrated to give N1-(2-chlorobenzyl)-4-methoxybenzene-1,2-diamine (1.4 g, 5 mmol, 100% yield) as brown oil used as the intermediate without further purification. LCMS (ESI): m/z 263.3[M+1]+.
-
- To a solution of N1-(2-chlorobenzyl)-4-methoxybenzene-1,2-diamine (1.3 g, 5.0 mmol) in DCM (30 mL) were added TEA (3.5 mL, 25 mmol) and the solution of 4-isobutylbenzoyl chloride (1.0 g, 5.0 mmol) in DCM (20 mL) at 0° C. After addition, the reaction mixture was stirred for 18 h at room temperature. It was then quenched with water (50 mL) and extracted with DCM (3×50 mL). The extracts were combined, washed with brine (2×100 mL), and dried over anhydrous Na2SO4. It was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give N-(2-((2-chlorobenzyl)amino)-5-methoxyphenyl)-4-isobutylbenzamide (1.3 g, 3.1 mmol, 62% yield) as yellow solid. LCMS (ESI): m/z 423.3[M+1]+.
-
- A mixture of N-(2-((2-chlorobenzyl)amino)-5-methoxyphenyl)-4-isobutylbenzamide (1.2 g, 2.8 mmol) in AcOH was stirred for 16 h at 120° C. After cooling to room temperature, the mixture was concentrated, and the residue was purified by column chromatography on silica gel (PE:EA=15:1) to give 1-(2-chlorobenzyl)-2-(4-isobutylphenyl)-5-methoxy-1H-benzo[d]imidazole (0.8 g, 2.0 mmol, 72% yield). LCMS (ESI): m/z 405.2[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.95 (d, J=6.8 Hz, 6H), 1.92-1.96 (m, 1H), 2.57 (d, J=7.2 Hz, 2H), 6.95 (s, 3H), 5.63 (s, 2H), 6.81 (d, J=7.6 Hz, 1H), 7.06-7.09 (m, 1H), 7.18 (d, J=8.8 Hz, 1H), 7.25-7.27 (m, 1H), 7.37-7.40 (m, 3H), 7.55 (d, J=7.2 Hz, 1H), 7.64-7.68 (m, 3H).
-
- A mixture of 1-(2-chlorobenzyl)-2-(4-isobutylphenyl)-5-methoxy-1H-benzo [d] imidazole (600 mg, 1.5 mmol) and t-butylthiol (1.3 g, 15 mmol) in CH2Cl2 (40 mL) was cooled to 0° C. AlCl3 (959 mg, 7.19 mmol) was added in portions over 5 min. After addition, the reaction mixture was stirred for 2 h, and then poured into the ice slowly. 1.0 N HCl (10 mL) was added and the mixture was extracted with CH2Cl2 (2×50 mL). The organic extracts were combined and washed with water (2×50 mL), dried (MgSO4), and concentrated. The crude product was purified by column chromatography on silica gel (PE:EA=10:1) to give 1-(2-chlorobenzyl)-2-(4-isobutylphenyl)-1H-benzo[d]imidazol-5-ol (400 mg, 1.0 mmol, 69% yield) as white solid. LCMS (ESI): m/z 391.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.86 (d, J=6.4 Hz, 6H), 1.84-1.90 (m, 1H), 2.53 (d, J=6.4 Hz, 2H), 5.62 (s, 2H), 6.92-6.89 (m, 2H), 7.10 (d, J=2.4 Hz, 1H), 7.23-7.27 (m, 1H), 7.32-7.37 (m, 4H), 7.51 (d, J=7.2 Hz, 1H), 7.59 (d, J=8.4 Hz, 2H).
-
- Synthetic route for example 21
-
- To a solution of 4-bromo-2-nitroaniline (5.0 g, 23 mmol) and 1-chloro-2-(chloromethyl)benzene (3.7 g, 23 mmol) in DMF (100 mL) was added DIPEA (1.65 mL, 90 mmol) at room temperature under N2. After addition, the reaction mixture was stirred for 48 h at 140° C. After cooling to room temperature, the mixture was quenched with water (100 mL) and extracted with EtOA (3×100 mL). The organic extracts were combined and washed with brine (3×100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give 4-bromo-N-(2-chlorobenzyl)-2-nitroaniline (2.7 g, 8 mmol, 35% yield) as red solid. LCMS (ESI): m/z 343[M+1]+.
-
- To a solution of 4-bromo-N-(2-chlorobenzyl)-2-nitroaniline (2.7 g, 7.9 mmol) in EtOH (50 mL) were added Fe (4.43 g, 79 mmol), NH4Cl (8.5 g, 158 mmol) and water (10 mL) at room temperature. After addition, the reaction mixture was stirred for 4 h at 80° C. After cooling to room temperature, the mixture was extracted with EtOAc (3×100 mL). The organic extracts were combined and washed with brine (3×100 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=3:1) to give 4-bromo-N1-(2-chlorobenzyl) benzene-1, 2-diamine (0.7 g, 2.2 mmol, 28% yield) as brown oil. LCMS (ESI): m/z 313.3[M+1]+.
-
- To a solution of 4-bromo-N1-(2-chlorobenzyl) benzene-1, 2-diamine 0.7 g, 2.3 mmol) in DCM (30 mL) were added TEA (3.7 mL, 26.5 mmol) and the solution of 2-(4-isobutylphenyl)propanoyl chloride (0.6 g, 2.25 mmol) in DCM (20 mL) at 0° C. After addition, the reaction mixture was stirred for 18 h at room temperature. The mixture was quenched with water (50 mL) and extracted with DCM (3×50 mL). The organic extracts were washed with brine (2×100 mL), dried over anydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=5:1) to give N-(5-bromo-2-((2-chlorobenzyl)amino)phenyl)-2-(4-isobutylphenyl)propanamide (720 mg, 1.45 mmol, 66% yield). LCMS (ESI): m/z 501.2[M+1]+.
-
- A mixture of N-(5-bromo-2-((2-chlorobenzyl)amino)phenyl)-2-(4-isobutylphenyl) propanamide (0.7 g, 1.4 mmol) in AcOH (20 mL) was stirred for 16 h at 120° C. After cooling to room temperature, the mixture was concentrated, and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give 5-bromo-1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-benzo[d]imidazole (0.6 g, 1.3 mmol, 93% yield). LCMS (ESI): m/z 483.2[M+1]+. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.84 (d, J=6.4 Hz, 6H), 1.72-1.79 (m, 1H), 1.88 (d, J=6.8 Hz, 3H), 2.35 (d, J=7.2 Hz, 2H), 4.33-4.38 (m, 1H), 5.32 (s, 2H), 6.14 (d, J=7.2 Hz, 1H), 6.94-7.03 (m, 3H), 7.11 (d, J=7.6 Hz, 2H), 7.18-7.22 (m, 1H), 7.39-7.43 (m, 2H), 8.20 (s, 1H).
-
- To a solution of 5-bromo-1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-benzo[d]imidazole (520 mg, 1.08 mmol) in DMF (20 mL) were added Pd(PPh3)4 (122 mg, 0.1 mmol) and Zn(CN)2 (127 mg, 1.08 mmol) at room temperature under N2. After addition, the reaction mixture was stirred for 16 hours at 80° C. After cooling to room temperature, the mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=5:1) to give 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-benzo[d]imidazole-5-carbonitrile (280 mg, 0.7 mmol, 70% yield). LCMS (ESI): m/z 428.3[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.84 (d, J=6.4 Hz, 6H), 1.72-1.79 (m, 1H), 1.84 (d, J=7.2 Hz, 3H), 2.35 (d, J=7.2 Hz, 2H), 4.22-4.27 (m, 1H), 5.30 (s, 2H), 6.11 (d, J=7.2 Hz, 1H), 6.94-7.00 (m, 3H), 7.06-7.08 (m, 2H), 7.16-7.21 (m, 2H), 7.39-7.41 (m, 1H), 7.48-7.50 (m, 1H), 8.27 (s, 1H).
-
- To a solution of 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-benzo[d] imidazole-5-carbonitrile (200 mg, 0.5 mmol) in MeOH (3 mL) were added water (10 mL) and KOH (263 mg, 5 mmol). The mixture was heated to 115° C. for 24 h and the organic solvente was evaporated. The residue was acidifed by 1.0 N HCl (aq) to pH=4. The resulting mixture was extracted with DCM (2×10 mL). The organic extracts were combined and washed with brine (2×10 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by pre-HPLC to give 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-benzo[d]imidazole-5-carboxylic acid (71 mg, 0.16 mmol, 32% yield). LCMS (ESI): m/z 447.2[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.78 (d, J=7.2 Hz, 6H), 1.68-1.72 (m, 4H), 2.30 (d, J=6.8 Hz, 2H), 4.45-4.50 (m, 1H), 5.38-5.62 (m, 2H), 6.10 (d, J=7.6 Hz, 1H), 6.94-7.0 (m, 3H), 7.10 (d, J=8.0 Hz, 1H), 7.11-7.23 (m, 1H), 7.37 (d, J=7.2 Hz, 1H), 7.44 (d, J=7.2 Hz, 1H), 7.80-7.83 (m, 1H), 8.31 (s, 1H), 12.98 (s, 1H).
-
- Synthetic route for example 22
-
- To a solution of 2-(4-isobutylphenyl)acetic acid (1.5 g, 7.8 mmol) in THF (50 mL) was added TEA (3.94 g, 39 mmol), N,O-dimethylhydroxylamine hydrochloride (0.94 g, 9.4 mmol) and HATU (4.45 g, 11.7 mmol) at room temperature. After addition, the reaction mixture was stirred for 18 h at room temperature. The mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=15:1) to give 2-(4-isobutylphenyl)-N-methoxy-N-methylacetamide (1.9 g, 8 mmol, 100% yield) as colorless oil. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.88 (d, J=6.4 Hz, 6H), 1.76-1.85 (m, 1H), 2.44 (d, J=7.2 Hz, 2H), 3.19 (s, 3H), 3.59 (s, 3H), 3.74 (s, 2H), 7.09 (d, J=8.0 Hz, 2H), 7.19 (d, J=8.0 Hz, 2H).
-
- To a solution of 2-(4-isobutylphenyl)-N-methoxy-N-methylacetamide (1.9 g, 8 mmol) in THF (50 mL) was added methylmagnesium bromide (12 mL, 12 mmol) at 0° C. After addition, the reaction mixture was stirred for 1 h at room temperature. It was quenched with saturated NH4Cl (aq, 50 mL) and extracted with EtOAc (3×50 mL). The organic extracts were washed with brine (2×50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (PE:EA=10:1) to give 1-(4-isobutyl phenyl)propan-2-one (1.1 g, 5.8 mmol, 73% yield) as colorless oil. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.89 (d, J=6.4 Hz, 6H), 1.82-1.88 (m, 1H), 2.14 (s, 3H), 2.45 (d, J=7.2 Hz 2H), 3.66 (s, 2H), 7.11 (s, 4H).
-
- To a suspension of (4-methoxyphenyl)hydrazine hydrochloride (8.75 g, 50 mmol) and 1-chloro-2-(chloromethyl)benzene (8.0 g, 50 mmol) in toluene (100 mL) was added triethylamine (13.78 mL, 100 mmol) and (n-Bu)4NI (0.55 g, 1.5 mmol) at room temperature. After addition, the temperature was allowed to slowly increase to 120° C., The reaction mixture was stirred for 4 h at 120° C. After cooling to room temperature, the mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=5:1) to give 1-(2-chlorobenzyl)-1-(4-methoxyphenyl)hydrazine (10.0 g, 38.5 mmol, 77% yield) as brown solid. LCMS (ESI): m/z 263.3[M+1]+.
-
- To a mixture of 1-(2-chlorobenzyl)-1-(4-methoxyphenyl)hydrazine (1.5 g, 5.8 mmol) in toluene (40 mL) were added 1-(4-isobutyl phenyl)propan-2-one (1.1 g, 5.8 mmol) and AcOH (20 mL). After addition, the reaction mixture was stirred for 24 h at room temperature. The mixture was concentrated and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give 1-(2-chlorobenzyl)-3-(4-isobutylphenyl)-5-methoxy-2-methyl-1H-indole (2.1 g, 5 mmol, 86% yield) as white solid. LCMS (ESI): m/z 418.4[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.97 (d, J=7.2 Hz, 6H), 1.91-1.97 (m, 1H), 2.38 (s, 3H), 2.54 (d, J=7.2 Hz, 2H), 3.83 (s, 3H), 5.39 (s, 2H), 6.34 (d, J=7.6 Hz, 1H), 6.79-6.82 (m, 1H), 7.03-7.09 (m, 2H), 7.16-7.20 (m, 2H), 7.25-7.27 (m, 2H), 7.40-7.45 (m, 3H).
-
- A solution of 1-(2-chlorobenzyl)-3-(4-isobutylphenyl)-5-methoxy-2-methyl-1H-indole (600 mg, 1.44 mmol) and t-butylthiol (1.3 g, 14.4 mmol) in CH2Cl2 (40 mL) was cooled to 0° C. AlCl3 (959 mg, 7.19 mmol) was added in portions over 5 min. The reaction mixture stirred for 2 h, and then poured into the ice slowly. 1.0 N HCl (aq, 10 mL) was added and the mixture was extracted with DCM (2×50 mL). The organic extracts were washed with water (2×50 mL), dried over anhydrous MgSO4, and concentrated. The crude product was purified by column chromatography on silica gel (PE:EA=3:1) to give 1-(2-chlorobenyl)-3-(4-isobutylphenyl)-2-methyl-1H-indol-5-ol (400 mg, 1 mmol, 69% yield) as white solid. LCMS (ESI): m/z 404.3[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 0.96 (d, J=6.8 Hz, 6H), 1.91-1.95 (m, 1H), 2.38 (s, 3H), 2.53 (d, J=7.2 Hz, 2H), 5.38 (s, 2H), 6.34 (d, J=7.6 Hz, 1H), 6.70-6.72 (m, 1H), 7.02-7.07 (m, 2H), 7.14-7.20 (m, 2H), 7.23-7.25 (m, 2H), 7.40-7.42 (m, 3H).
-
- The compound 56 was prepared by the method similar to example 22. LCMS (ESI): m/z 404.3[M+1]+. 1HNMR (400 MHz, DMSO-d6): δ (ppm) 0.90 (d, J=6.4, 6H), 1.89-1.84 (m, 1H), 2.47 (d, J=7.2, 2H), 3.79 (s, 3H), 5.51 (s, 2H), 6.74 (d, J=6.8, 1H), 6.84-6.81 (m, 1H), 7.24-7.21 (m, 3H), 7.35-7.28 (m, 3H), 7.51 (d, J=7.6 Hz, 1H), 7.57 (d, J=8.0 Hz, 2H), 7.70 (s, 1H).
-
- Synthetic route for example 24
-
- A solution of LDA (60 mL, 0.12 mol, 2.0 M in THF) was diluted in THF (150 mL). The mixture was cooled to −78° C. Ethyl isobutyrate (10.2 g, 0.1 mol) was added dropwise, and the temperature was maintained below −60° C. The mixture was stirred at −70° C.˜−65° C. for 20 min. Methyl 2-bromoacetate (15.3 g, 0.1 mol) was added dropwise. The reaction mixture was then allowed to warm to room temperature and stirred for 18 h. The mixture was quenched with saturated NH4Cl (aq). The organic layer was separated and the aqueous layer was extracted with EtOAc (2×100 mL). The organic layers were combined and dried over anhydrous Na2SO4, filtered and concentrated to give dimethyl 2,2-dimethylsuccinate (10 g, 57 mmol) as brown oil used as the intermediate without further purification. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.27 (s, 6H), 2.60 (s, 2H), 3.66 (s, 3H), 3.72 (s, 3H).
-
- To a solution of dimethyl 2, 2-dimethylsuccinate (1.74 g, 10 mmol) in MeOH (20 mL) were added KOH (0.56 g, 10 mmol) and water (10 mL) at room temperature. After addition, the reaction mixture was stirred for 2 h at room temperature. It was quenched with 1.0 N HCl (aq, 30 mL), extracted with EtOAc (3×50 mL). The organic extracts were washed with brine (2×100 mL), dried over Na2SO4 and concentrated to give 4-methoxy-3,3-dimethyl-4-oxobutanoic acid (1.6 g, 10 mmol) as brown oil used as the intermediate without further purification.
-
- To a solution of N1-(2-chlorobenzyl)-4-methoxybenzene-1,2-diamine (2.62 g, 10 mmol) in THF (50 mL) were added 4-methoxy-3,3-dimethyl-4-oxobutanoic acid (1.6 g, 10 mmol), TEA (4.2 mL, 30 mmol) and HATU (5.7 g, 15 mmol) at room temperature. After addition, the reaction mixture was stirred for 24 h at room temperature. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (PE:EA=10:1) to give methyl 4-((2-((2-chlorobenzyl) amino)-5-methoxyphenyl) amino)-2,2-dimethyl-4-oxobutanoate (1.2 g, 3 mmol, 30% yield over three steps) as brown solid. LCMS (ESI): m/z 405.3[M+1]+.
-
- The mixture of methyl 4-((2-((2-chlorobenzyl)amino)-5-methoxyphenyl)amino)-2,2-dimethyl-4-oxobutanoate (1.2 g, 3.0 mmol) in AcOH (30 mL) was stirred for 16 h at 120° C. After cooling to room temperature, the mixture was concentrated, and the residue was purified by column chromatography on silica gel (PE:EA=15:1) to give 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-5-methoxy-1H-benzo[d]imidazole (0.6 g, 1.6 mmol, 53% yield). LCMS (ESI): m/z 405.3[M+1]+. 1HNMR (400 MHz, CDCl3): δ (ppm) 1.39 (s, 6H), 3.02 (s, 2H), 3.67 (s, 3H), 3.85 (s, 3H), 5.42 (s, 2H), 6.36 (d, J=7.6 Hz, 1H), 6.82 (dd, J=8.8, 2.4 Hz, 1H), 7.00 (d, J=8.8 Hz, 1H), 7.07 (t, J=7.6 Hz, 1H), 7.22 (t, J=7.2 Hz, 1H), 7.28 (dd, J=7.6, 2.0 Hz, 1H 1H), 7.43 (d, J=8.0 Hz, 1H).
-
- To a mixture of 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-5-methoxy-1H-benzo[d]imidazole (600 mg, 1.55 mmol) in THF (10 mL) and MeOH (10 mL) were added LiOH·H2O (653 mg, 15.5 mmol) and H2O (20 mL). The mixture was stirred for 5 h at 65° C. After cooling to room temperature, the mixture was concentrated. The residue was diluted with water (30 mL) and the solution was acidified with 2.0 N HCl (aq) to pH=4˜5. The mixture was extracted with DCM (3×20 mL). The organic extracts were combined and dried over anhydrous Na2SO4, filtered and concentrated. The residue was recrystallizated from EtOAc:PE=1:3 to give 3-(1-(2-chlorobenzyl)-5-methoxy-1H-benzo[d]imidazol-2-yl)-2,2-dimethylpropanoic acid (250 mg, 0.67 mmol, 43% yield) as white solid. LCMS (ESI): m/z 373.3[M+1]+. 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 1.26 (s, 6H), 2.97 (s, 2H), 3.77 (s, 3H), 5.53 (s, 2H), 6.42 (d, J=7.6 Hz, 1H), 6.77 (dd, J=8.8, 2.4 Hz, 1H), 7.14 (d, J=2.4 Hz, 1H), 7.17-7.24 (m, 2H), 7.32 (t, J=7.6 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 12.21 (br s, 1H).
- To test the effect of the novel compounds on the proliferation of tumor cell, we isolated tumor cells from medulloblastoma developed from mice with deficiency in Patched1 gene. Tumor cells were plated in vitro as previously described, and treated with various concentration of compounds for 48 hours. Tumor cells cultured were then harvested to measure cell survival based on MTT assay. The IC50 value for each compound was calculated using Prism the statistical software.
- Table 1 below summarizes the IC50 data obtained using MB assay for exemplary compounds of the invention. IC50 values are shown as A, B, C, or D. A represents IC50 value between 1.0 μM and 5.0 μM; B is between 5.0 μM and 10 μM; C is between 10 μM to 20 μM; and D indicates greater than 20 μM.
-
TABLE 1 IC50 results of exemplary compounds Compound Number Structure IC50 1 A 2 D 3 A 4 D 5 D 6 C 7 C 8 C 9 C 10 D 11 B 12 D 13 C 14 D 15 D 16 C 17 D 18 D 19 D 20 A 21 D 22 D 23 B 24 A 25 D 26 A 27 B 28 D 29 D 30 D 31 D 32 A 33 D 34 B 35 B or 36 B or 37 C or 38 A or 39 B 40 D 41 D 42 D 43 D 44 D 45 D 46 C 47 D 48 D 49 A 50 C 51 B 52 D 53 C 54 D 55 A 56 D 57 D 58 D - It will be understood by those of skill in the art that the various embodiments and examples of the present invention described herein are illustrative only and are not intended to limit the scope of the present invention and numerous modifications can be made without departing from the spirit and scope of the present invention.
Claims (16)
1. A method of treating a disease or disorder associated with the hedgehog pathway, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of formula (II):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
R1 is C1-8 alkyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, C6-10 aryl, —(C1-6 alkylene)-C3-6 cycloalkyl, —(C1-6 alkylene)-C6-10 aryl, or —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl);
R2 is hydrogen, C1-8 alkyl, C6-10 aryl, —C(O)OR8, —C(O)NRaRb, —(C1-6 alkylene)-C6-10 aryl, —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl), —(C1-6 alkylene)-C(O)OR8, or —(C1-6 alkylene)-C(O)NRaRb;
R3 is hydrogen, halogen, hydroxyl, C1-6 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, or —C(O)OR11;
R4 is hydrogen, halogen, hydroxyl, or C1-6 alkyl;
R5 is hydrogen, C1-8 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)nR10 (n is 0, 1, or 2);
R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
R9 is hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
R10 is C1-10 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
wherein any said alkyl or cycloalkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said aryl or heteroaryl is optionally substituted by one, two or three substituents independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, —C(O)OR11, —(C1-6 alkylene)-OR12, —(C1-6 alkylene)-CN, —(C1-6 alkylene)-C(O)OR11, and —(C1-6 alkylene)-C(O)NRaRb;
R11 is hydrogen or C1-6 alkyl;
R12 is hydrogen or C1-6 alkyl; and
Ra and Rb are each independently hydrogen, C1-6 alkyl, C6-10 aryl, or benzyl;
provided, however, that the following compound is excluded:
2. The method of claim 1 , wherein:
R1 is selected from the group consisting of benzyl, C3-6 cycloalkyl-methyl, 5- or 6-membered heterocyclyl-methyl, and 5 or 6-membered heteroaryl-methyl, each optionally substituted; and
R2 is C1-6 alkyl, phenyl, or 5-membered heteroaryl, wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of phenyl, 5- or 6-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said heteroaryl or phenyl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, cyano, C1-4 alkyl, C1-4 alkoxy, —C(O)OR11, —(C1-4 alkylene)-OR12, —(C1-4 alkylene)-CN, and —(C1-4 alkylene)-C(O)OR11;
R3 is hydrogen, C1-6 alkyl, halogen, hydroxyl, C1-4 alkoxy, C3-6 cycloalkyl, or —C(O)OR11;
R4 is hydrogen, halogen, hydroxyl, or C1-6 alkyl;
R5 is C1-8 alkyl, phenyl optionally substituted by a C1-6 alkyl, 5- to 6-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)R10 (n is 0, 1, or 2), wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, C(O)NRaRb, and —(C1-8 alkyl)-(C6-10 aryl); and any aryl or heteroaryl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and cyano;
R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or benzyl;
R9 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, 5- to 10-membered heteroaryl, or —(C1-4 alkylene)-phenyl;
R10 is C1-8 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or benzyl;
R11 is hydrogen or C1-6 alkyl;
R12 is hydrogen or C1-6 alkyl; and
Ra and Rb are independently hydrogen or C1-6 alkyl.
3. The method of claim 1 , wherein:
R1 is selected from the group consisting from C1-C6 alkyl,
wherein each X is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or CN; and each R13 is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R2 is selected from the group consisting of hydrogen, C1-C6 alkyl,
wherein Rx is halogen, —(CH2)nCN, or —(CH2)nOR14, wherein each n is 0, 1, or 2; each R14 is independently H or C1-C6 alkyl; and Ra and Rb are independently hydrogen or C1-6 alkyl;
R3 is selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, C1-C6 haloalkyl, and —C(O)OR15, wherein R15 is H or C1-C6 alkyl;
R4 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, hydroxyl, and C1-C6 alkoxy; and/or
R5 is selected from the group consisting of hydrogen, C1-C8 alkyl, 5-membered heteroaryl,
6. The method of claim 1 , wherein the disease or disorder is selected from medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer, and chondrosarcoma.
7. The method of claim 5 , wherein the disease or disorder is selected from medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer, and chondrosarcoma.
8. A method of treating a disease or disorder associated with the hedgehog pathway, comprising administering to a subject in need of treatment a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (II):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
R1 is C1-8 alkyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, C6-10 aryl, —(C1-6 alkylene)-C3-6 cycloalkyl, —(C1-6 alkylene)-C6-10 aryl, or —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl);
R2 is hydrogen, C1-8 alkyl, C6-10 aryl, —C(O)OR8, —C(O)NRaRb, —(C1-6 alkylene)-C6-10 aryl, —(C1-6 alkylene)-(5- to 10-membered heteroaryl or heterocyclyl), —(C1-6 alkylene)-C(O)OR8, or —(C1-6 alkylene)-C(O)NRaRb;
R3 is hydrogen, halogen, hydroxyl, C1-6 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, or —C(O)OR11;
R4 is hydrogen, halogen, hydroxyl, or C1-6 alkyl;
R5 is hydrogen, C1-8 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)nR10 (n is 0, 1, or 2);
R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
R9 is hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
R10 is C1-10 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or —(C1-6 alkylene)-C6-10 aryl;
wherein any said alkyl or cycloalkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said aryl or heteroaryl is optionally substituted by one, two or three substituents independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, —C(O)OR11, —(C1-6 alkylene)-OR12, —(C1-6 alkylene)-CN, —(C1-6 alkylene)-C(O)OR11, and —(C1-6 alkylene)-C(O)NRaRb;
R11 is hydrogen or C1-6 alkyl;
R12 is hydrogen or C1-6 alkyl; and
Ra and Rb are each independently hydrogen, C1-6 alkyl, C6-10 aryl, or benzyl;
provided, however, that the following compound is excluded:
9. The method of claim 8 , wherein:
R1 is selected from the group consisting of benzyl, C3-6 cycloalkyl-methyl, 5- or 6-membered heterocyclyl-methyl, and 5 or 6-membered heteroaryl-methyl, each optionally substituted; and
R2 is C1-6 alkyl, phenyl, or 5-membered heteroaryl, wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of phenyl, 5- or 6-membered heteroaryl, C(O)OR11, OR12, and C(O)NRaRb; and any said heteroaryl or phenyl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, cyano, C1-4 alkyl, C1-4 alkoxy, —C(O)OR11, —(C1-4 alkylene)-OR12, —(C1-4 alkylene)-CN, and —(C1-4 alkylene)-C(O)OR11;
R3 is hydrogen, C1-6 alkyl, halogen, hydroxyl, C1-4 alkoxy, C3-6 cycloalkyl, or —C(O)OR11;
R4 is hydrogen, halogen, hydroxyl, or C1-6 alkyl;
R5 is C1-8 alkyl, phenyl optionally substituted by a C1-6 alkyl, 5- to 6-membered heteroaryl, —C(O)OR8, —C(O)R9, or —S(O)R10 (n is 0, 1, or 2), wherein the C1-8 alkyl is optionally substituted by one or two substituents independently selected from the group consisting of C6-10 aryl, 5- to 10-membered heteroaryl, C(O)OR11, OR12, C(O)NRaRb, and —(C1-8 alkyl)-(C6-10 aryl); and any aryl or heteroaryl is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and cyano;
R8 is hydrogen, C1-6 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or benzyl;
R9 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, 5- to 10-membered heteroaryl, or —(C1-4 alkylene)-phenyl;
R10 is C1-8 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, or benzyl;
R11 is hydrogen or C1-6 alkyl;
R12 is hydrogen or C1-6 alkyl; and
Ra and Rb are independently hydrogen or C1-6 alkyl.
10. The method of claim 8 , wherein:
R1 is selected from the group consisting from C1-C6 alkyl,
wherein each X is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or CN; and each R13 is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R2 is selected from the group consisting of hydrogen, C1-C6 alkyl,
wherein Rx is halogen, —(CH2)nCN, or —(CH2)nOR14, wherein each n is 0, 1, or 2; each R14 is independently H or C1-C6 alkyl; and Ra and Rb are independently hydrogen or C1-6 alkyl;
R3 is selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, C1-C6 haloalkyl, and —C(O)OR15, wherein R15 is H or C1-C6 alkyl;
R4 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, hydroxyl, and C1-C6 alkoxy; and/or
R5 is selected from the group consisting of hydrogen, C1-C8 alkyl, 5-membered heteroaryl,
13. The method of claim 8 , wherein the disease or disorder is selected from medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer, and chondrosarcoma.
14. The method of claim 12 , wherein the disease or disorder is selected from medulloblastoma, basal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, advanced stomach cancer, oesophageal cancer, glioblastoma multiforme, acute leukemia, chronic myeloid leukemia, myelofibrosis, essential thrombocythaemia, metastatic colorectal cancer, small-cell lung cancer, and chondrosarcoma.
15. The method of claim 8 , wherein the pharmaceutical composition is a formulation selected from capsules, cachets, pills, tablets, lozenges, powders, granules, pastilles, solutions, suspensions, emulsions, elixirs, and syrups.
16. The method of claim 8 , wherein said administering is selected from oral, nasal, topical, rectal, vaginal, and/or parenteral administrations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/366,553 US20240043423A1 (en) | 2018-06-25 | 2023-08-07 | Compounds and methods for treatment of hedgehog pathway associated conditions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862689470P | 2018-06-25 | 2018-06-25 | |
PCT/IB2019/055338 WO2020003119A1 (en) | 2018-06-25 | 2019-06-25 | Compounds and methods for treatment of hedgehog pathway associated conditions |
US202017255413A | 2020-12-22 | 2020-12-22 | |
US18/366,553 US20240043423A1 (en) | 2018-06-25 | 2023-08-07 | Compounds and methods for treatment of hedgehog pathway associated conditions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/055338 Division WO2020003119A1 (en) | 2018-06-25 | 2019-06-25 | Compounds and methods for treatment of hedgehog pathway associated conditions |
US17/255,413 Division US11718614B2 (en) | 2018-06-25 | 2019-06-25 | Compounds and methods for treatment of hedgehog pathway associated conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240043423A1 true US20240043423A1 (en) | 2024-02-08 |
Family
ID=68986099
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/255,413 Active US11718614B2 (en) | 2018-06-25 | 2019-06-25 | Compounds and methods for treatment of hedgehog pathway associated conditions |
US18/366,553 Pending US20240043423A1 (en) | 2018-06-25 | 2023-08-07 | Compounds and methods for treatment of hedgehog pathway associated conditions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/255,413 Active US11718614B2 (en) | 2018-06-25 | 2019-06-25 | Compounds and methods for treatment of hedgehog pathway associated conditions |
Country Status (7)
Country | Link |
---|---|
US (2) | US11718614B2 (en) |
EP (1) | EP3810573A4 (en) |
JP (1) | JP2021529785A (en) |
CN (1) | CN113329996B (en) |
AU (1) | AU2019294083A1 (en) |
CA (1) | CA3104599A1 (en) |
WO (1) | WO2020003119A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1241660A (en) | 1984-06-25 | 1988-09-06 | Yvan Guindon | Indole-2-alkanoic acids |
IL84796A (en) * | 1986-12-17 | 1992-03-29 | Merck Frosst Canada Inc | Substituted n-benzyl-indoles and pharmaceutical compositions containing them |
FR2658511B1 (en) * | 1990-02-16 | 1992-06-19 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE AND AZABENZIMIDAZOLE DERIVATIVES, THROMBOXANE RECEPTOR ANTAGONISTS; THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
US7405302B2 (en) * | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
UA95084C2 (en) * | 2005-11-04 | 2011-07-11 | Амира Фармасутикалз, Инк. | 5-lipoxygenase-activating protein (flap) inhibitors |
US8546431B2 (en) * | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
EP2408449A4 (en) * | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | Methods and compositions of treating a flaviviridae family viral infection |
JP2012211085A (en) * | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | Hedgehog signal inhibitor |
AR084433A1 (en) * | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP2698367A1 (en) | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
US9616056B2 (en) * | 2013-03-15 | 2017-04-11 | Institute For Cancer Research | Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma |
CA2943815C (en) * | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
CN109678785A (en) * | 2018-12-20 | 2019-04-26 | 苏州麦迪耐斯医药科技有限公司 | A kind of compound and its preparation method and application |
-
2019
- 2019-06-25 AU AU2019294083A patent/AU2019294083A1/en not_active Abandoned
- 2019-06-25 US US17/255,413 patent/US11718614B2/en active Active
- 2019-06-25 WO PCT/IB2019/055338 patent/WO2020003119A1/en unknown
- 2019-06-25 JP JP2020573456A patent/JP2021529785A/en active Pending
- 2019-06-25 CA CA3104599A patent/CA3104599A1/en active Pending
- 2019-06-25 EP EP19824574.8A patent/EP3810573A4/en not_active Withdrawn
- 2019-06-25 CN CN201980054075.9A patent/CN113329996B/en active Active
-
2023
- 2023-08-07 US US18/366,553 patent/US20240043423A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3810573A1 (en) | 2021-04-28 |
US11718614B2 (en) | 2023-08-08 |
CA3104599A1 (en) | 2020-01-02 |
AU2019294083A1 (en) | 2021-01-21 |
EP3810573A4 (en) | 2021-12-08 |
WO2020003119A1 (en) | 2020-01-02 |
US20210214353A1 (en) | 2021-07-15 |
JP2021529785A (en) | 2021-11-04 |
CN113329996A (en) | 2021-08-31 |
CN113329996B (en) | 2023-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7154002B1 (en) | Histone deacetylase inhibitors | |
CA2759241C (en) | Novel anti-inflammatory agents | |
US8258175B2 (en) | Isoindolin-1-one derivatives | |
EP2125810B1 (en) | Mapk/erk kinase inhibitors | |
US8822518B2 (en) | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | |
JP2006520796A (en) | Histone deacetylase inhibitor | |
JP2009525955A (en) | Histone deacetylase inhibitor | |
US20130281398A1 (en) | Treatment of diseases by epigenetic regulation | |
US8088783B2 (en) | MAPK/ERK kinase inhibitors | |
US20050159470A1 (en) | Histone deacetylase inhibitors | |
US11884682B2 (en) | Compounds and their uses as MIF inhibitors | |
KR20060017545A (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
US20080312307A1 (en) | Mapk/erk kinase inhibitors | |
US20100240642A1 (en) | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | |
US20060229324A1 (en) | Quinazolin-4-one derivatives | |
US11718614B2 (en) | Compounds and methods for treatment of hedgehog pathway associated conditions | |
KR20060017544A (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
US6939887B2 (en) | Benzimidazolidinone derivatives | |
US10519105B2 (en) | KCNQ2-5 channel activator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUZHOU MEDNES PHARMA TECH CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DU, FANG;HU, XIAOWEI;LIANG, YUGANG;REEL/FRAME:064514/0566 Effective date: 20220804 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |